Hawkins Inc.
Annual Report 2022

Plain-text annual report

☑ ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended April 3, 2022 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-7647 HAWKINS, INC. (Exact Name of Registrant as Specified in its Charter) Minnesota (State of Incorporaon) 2381 Rosegate, Roseville, Minnesota (Address of Principal Execuve Offices) 41-0771293 (I.R.S. Employer Idenficaon No.) 55113 (Zip Code) Title of each class Common Shares, par value $.01 per share (612) 331-6910 (Registrant’s Telephone Number, Including Area Code) Securies registered pursuant to Secon 12(b) of the Act: Trading Symbol: HWKN Securies registered pursuant to Secon 12(g) of the Act: None Name of exchange on which registered: Nasdaq Stock Market LLC Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securies Act. Yes ☑ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Secon 13 or Secon 15(d) of the Act. Yes ☐ No ☑ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Secon 13 or 15(d) of the Securies Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐ Indicate by check mark whether the registrant has submied electronically every Interacve Data File required to be submied pursuant to Rule 405 of Regulaon S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☑ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporng company, or an emerging growth company. See the definions of “large accelerated filer,” “accelerated filer,” “smaller reporng company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☑ Non-accelerated filer ☐ Accelerated filer ☐ Smaller reporng company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transion period for complying with any new or revised financial accounng standards provided pursuant to Secon 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant has filed a report on and aestaon to its management’s assessment of the effecveness of its internal control over financial reporng under Secon 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounng firm that prepared or issued its audit report. ☑ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑ The aggregate market value of vong stock held by non-affiliates of the Registrant on September 26, 2021 (the last business day of the Registrant’s most recently completed second fiscal quarter) was approximately $706.8 million based upon the closing sale price for the Registrant’s common shares on that date as reported by The Nasdaq Stock Market LLC, excluding all shares held by officers and directors of the Registrant and by the Trustees of the Registrant’s Employee Stock Ownership Plan and Trust. As of May 13, 2022, the Registrant had 21,078,132 shares of common shares outstanding. DOCUMENTS INCORPORATED BY REFERENCE Porons of our definive Proxy Statement for the annual meeng of shareholders to be held August 3, 2022, are incorporated by reference in Part III of this Annual Report on Form 10-K FORWARD-LOOKING STATEMENTS The informaon presented in this Annual Report on Form 10-K contains forward-looking statements within the meaning of Secon 21E of the Securies Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements have been made pursuant to the provisions of the Private Securies Ligaon Reform Act of 1995. These statements are not historical facts, but rather are based on our current expectaons, esmates and projecons, and our beliefs and assumpons. Words such as “ancipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “esmate,” “will” and similar expressions may idenfy forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertaines and other factors, some of which are beyond our control and are difficult to predict. These factors could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These risks and uncertaines are described in the risk factors and elsewhere in this Annual Report on Form 10-K. We cauon you not to place undue reliance on these forward-looking statements, which reflect our management’s view only as of the date of this Annual Report on Form 10-K. We are not obligated to update these statements or publicly release the result of any revisions to them to reflect events or circumstances aer the date of this Annual Report on Form 10-K or to reflect the occurrence of unancipated events. As used in this Annual Report on Form 10-K, except where otherwise stated or indicated by the context, “Hawkins,” “we,” “us,” “the Company,” “our,” or “the Registrant” means Hawkins, Inc. References to "fiscal 2023" means our fiscal year ending April 2, 2023, “fiscal 2022” means our fiscal year ended April 3, 2022, “fiscal 2021” means our fiscal year ended March 28, 2021, “fiscal 2020” means our fiscal year ended March 29, 2020, and “fiscal 2019” means our fiscal year ended March 31, 2019. ii Hawkins, Inc. Annual Report on Form 10-K For the Fiscal Year Ended April 3, 2022 ITEM 1. ITEM 1A. ITEM 1B. ITEM 2. ITEM 3. ITEM 4. ITEM 5. ITEM 6. ITEM 7. ITEM 7A. ITEM 8. ITEM 9. ITEM 9A. ITEM 9B. ITEM 9C. ITEM 10. ITEM 11. ITEM 12. ITEM 13. ITEM 14. Business Risk Factors Unresolved Staff Comments Properes Legal Proceedings Mine Safety Disclosures PART I PART II Market for the Company’s Common Equity, Related Shareholder Maers, and Issuer Purchases of Equity Securies Reserved Management’s Discussion and Analysis of Financial Condion and Results of Operaons Quantave and Qualitave Disclosures about Market Risk Financial Statements and Supplementary Data Changes in and Disagreements with Accountants on Accounng and Financial Disclosure Controls and Procedures Other Informaon Disclosure Regarding Foreign Jurisdicons That Prevent Inspecons PART III Directors, Execuve Officers, and Corporate Governance Execuve Compensaon Security Ownership of Certain Beneficial Owners and Management And Related Stockholder Maers Certain Relaonships and Related Transacons, and Director Independence Principal Accountant Fees and Services ITEM 15. ITEM 16. Exhibits and Financial Statement Schedules Form 10-K Summary PART IV iii Page 1 4 11 12 12 12 13 14 14 21 22 48 48 49 49 50 51 51 51 51 52 54 ITEM 1. BUSINESS PART I We are a leading specialty chemical and ingredients company that formulates, distributes, blends and manufactures products for our Industrial, Water Treatment and Health and Nutrion customers. We believe that we create value for our customers through superb service and support, quality products, personalized applicaons and trustworthy, creave employees. We conduct our business in three segments: Industrial, Water Treatment, and Health and Nutrion. Industrial Segment. Our Industrial Group specializes in providing industrial chemicals, products and services to industries such as agriculture, chemical processing, electronics, energy, food, pharmaceucal and plang. This group’s principal products are acids, alkalis and food-grade and pharmaceucal salts and ingredients. The Industrial Group: • Manufactures sodium hypochlorite (bleach), agricultural products and certain food-grade and pharmaceucal products, including liquid phosphates, lactates and other blended products; • Receives, stores and distributes various chemicals in bulk quanes, including liquid causc soda, sulfuric acid, hydrochloric acid, urea, phosphoric acid, aqua ammonia and potassium hydroxide; • Repackages water treatment chemicals for our Water Treatment Group and bulk industrial chemicals to sell in smaller quanes to our customers; • Performs custom blending of chemicals according to customer formulas and specificaons; and • Performs contract and private label bleach packaging. The group’s sales are concentrated primarily in the central United States, while the group’s products sold into the food and pharmaceucal markets are sold naonally. The Industrial Group relies on a specially trained sales staff that works directly with customers on their specific needs. The group conducts its business primarily through manufacturing locaons and terminal operaons. Agricultural sales within this group tend to be seasonal, with higher sales due to the applicaon of ferlizer during the planng season of March through June given the regions of the country where we are located. Water Treatment Segment. Our Water Treatment Group specializes in providing chemicals, products, equipment, services and soluons for potable water, municipal and industrial wastewater, industrial process water, non-residenal swimming pool water and agricultural water. This group has the resources and flexibility to treat systems ranging in size from a single small well to a mul-million-gallon-per-day facility. The group ulizes delivery routes operated by our employees who typically serve as route driver, salesperson and trained technician to deliver our products and diagnose our customers’ water treatment needs. We believe that the high level of service provided by these individuals allows us to serve as the trusted water treatment expert for many of the municipalies and other customers that we serve. We also believe that there are significant synergies between our Water Treatment and Industrial Groups in that we are able to obtain a compeve cost posion on many of the chemicals sold by the Water Treatment Group due to the volumes of these chemicals purchased by our Industrial Group. In addion, our Industrial and Water Treatment groups share certain resources, which leverage fixed costs across both groups. The Water Treatment group operates out of 37 warehouses supplying products and services to customers primarily in the central United States, and along the south from Florida to Texas. In fiscal 2022, we added four locaons, all by acquision. We expect to invest in exisng and new branches to expand the group’s geographic coverage. Our Water Treatment Group has historically experienced higher sales during April to September, primarily due to a seasonal increase in chemicals used by municipal water treatment facilies. 1 Health and Nutrion Segment. Our Health and Nutrion Group specializes in providing ingredient distribuon, processing and formulaon soluons to manufacturers of nutraceucal, funconal food and beverage, personal care, dietary supplement and other nutrional food, health and wellness products. This group offers a diverse product porolio including minerals, vitamins and amino acids, excipients, joint products, botanicals and herbs, sweeteners and enzymes. The Health and Nutrion Group relies on a specially trained sales and product development staff that works directly with customers on their specific needs. The group’s extensive product porolio combined with value-added services, including product formulaon, sourcing and distribuon, processing and blending and quality control and compliance, posions this group as a one-stop ingredient soluons provider to its customers. The group operates out of facilies in California and New York and its products are sold naonally and, in certain cases, internaonally. Raw Materials. We have numerous suppliers, including many of the major chemical producers in the United States. We source our health and nutrion ingredients from a wide array of domesc and internaonal vendors. We typically have distributorship agreements or supply contracts with our suppliers that are periodically renewed. We believe that most of the products we purchase can be obtained from alternave sources should exisng relaonships be terminated. We are dependent upon the availability of our raw materials. While we believe that we have adequate sources of supply for our raw material and product requirements, we cannot be sure that supplies will be consistently available in the future. In the event that certain raw materials become generally unavailable, suppliers may extend lead mes or limit or cut off the supply of materials to us. As a result, we may not be able to supply or manufacture products for our customers. Intellectual Property. Our intellectual property porolio is of economic importance to our business. When appropriate, we have pursued, and we will connue to pursue, patents covering our products. We also have obtained certain trademarks for our products to disnguish them from our competors’ products. We regard many of the formulas, informaon and processes that we generate and use in the conduct of our business as proprietary and protectable under applicable copyright, patent, trademark, trade secret and unfair compeon laws. Customer Concentraon. In fiscal 2022, none of our customers accounted for 10% or more of our total sales. Compeon. We operate in a compeve industry and compete with many producers, distributors and sales agents offering products equivalent to substanally all of the products we offer. Many of our competors are larger than we are and may have greater financial resources, although no one competor is dominant in all of the markets we serve. We compete by offering quality products with outstanding customer service at compeve prices coupled with value-added services or product formulaon where needed. Because of our long-standing relaonships with many of our suppliers, we are oen able to leverage those relaonships to obtain products when supplies are limited or to obtain compeve pricing. Working Capital. Due to the nature of our operaons, which includes purchases of large quanes of bulk chemicals, the ming of purchases can result in significant changes in working capital and the resulng operang cash flow. Historically, our cash requirements for working capital increase during the period from March through November as causc soda inventory levels increase with most of our barges received during this period. Regulatory Maers. We are subject to numerous federal, state and local environmental, health and safety laws and regulaons in the jurisdicons in which we operate, including the management, storage, transportaon and disposal of chemicals and wastes; product regulaon; air water and soil contaminaon; and the invesgaon and cleanup of any spills or releases that may result from our management, handling, storage, sale, or transportaon of chemicals and other products. In addion, societal concerns regarding the safety of chemicals in commerce and their potenal impact on the environment have resulted in a growing trend towards increasing levels of product safety and environmental protecon regulaons. These concerns have led to, and could connue to result in, more stringent regulatory intervenon by governmental authories. In addion, we operate a fleet of more than 200 commercial vehicles, primarily in our Water Treatment Group, which are highly regulated, including by the U.S. Department of Transportaon (“DOT”). The DOT governs transportaon maers including authorizaon to engage in motor carrier service, including the necessary permits to conduct our businesses, equipment operaon, and safety. 2 The manufacture, packaging, labeling, adversing, promoon, distribuon and sale of our agricultural, food, pharmaceucal, pescide and health and nutrion products are subject to regulaon by numerous naonal and local governmental agencies in the United States and other countries. The primary regulatory bodies in the United States are the Food and Drug Administraon (the “FDA”), the Environmental Protecon Agency, the United States Department of Agriculture and the Federal Trade Commission, and we are also subject to similar regulators in other countries. In parcular, the FDA’s current good manufacturing pracces (“GMPs”) describe policies and procedures designed to ensure that nutraceucals, pharmaceucals and dietary supplements are produced in a quality manner, do not contain contaminants or impuries, and are accurately labeled and cover the manufacturing, packaging, labeling and storing of supplements, with requirements for quality control, design and construcon of manufacturing plants, tesng of ingredients and final products, record keeping, and complaints processes. Further informaon related to government regulaon applicable to our business is included in this Annual Report on Form 10-K, in Part I, Item 1A - Risk Factors. Human Capital. Our team is a key to our success and we are commied to creang a workplace that aracts top talent, develops leaders and drives performance on behalf of our customers and shareholders. We strive to recruit the best people for the job regardless of race, color, naonality, gender, age, disability, sexual orientaon or any other status protected by law. It is our policy to comply fully with all applicable laws relang to discriminaon in the workplace and are commied to advancing an inclusive, collaborave and respecul culture. The health and safety of our employees is our highest priority. We work to ensure our employees have a thorough understanding of health and safety precauons that need to be taken in all business funcons. Specific safety iniaves include accident prevenon work, improving process controls, safety training, safety commiees, safety audits, incident invesgaon and improvement measures. We have ensured the safety of our employees and our customers during the COVID-19 pandemic by implemenng conngency and connuity plans to respond quickly and appropriately to idenfied risks, safe work pracces in accordance with the guidance provided by the US Centers for Disease Control and Prevenon ("CDC"). Through communicaon, enhanced resources and leadership, we were able to support our employees, serve our customers and keep our facilies operang and safe during the pandemic. We strive to provide employees with compeve wages commensurate with their skill levels, experience, knowledge and the regional market. Full-me employees are eligible for health, dental and vision insurance, paid and unpaid leaves, 401(K) plan, rerement plans, life and disability/accident coverage and our employee assistance program. As of April 3, 2022, we had 813 employees across the United States, of which 807 were full-me employees,. Approximately 38% of our employees were female or racially and ethnically diverse, and approximately 10% were covered by a collecve bargaining agreement. Of the eight members of our Board of Directors, two are female, six are male, one is Asian American and seven are white. Available Informaon. Our Internet address is www.hawkinsinc.com. We have made available, free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports, as soon as reasonably praccable aer we electronically file these materials with, or furnish them to, the Securies and Exchange Commission. Reports of beneficial ownership filed by our directors and execuve officers pursuant to Secon 16(a) of the Exchange Act are also available on our website. We are not including the informaon contained on our website as part of, or incorporang it by reference into, this Annual Report on Form 10-K. The SEC also maintains an internet site that contains reports, proxy and informaon statements, and other informaon regarding our company at hp://www.sec.gov. 3 ITEM 1A. RISK FACTORS You should consider carefully the following material factors regarding risks relang to an investment in our securies and when reading the informaon, including the financial informaon, contained in this Annual Report on Form 10-K. Shareholders are cauoned that these and other factors may affect future performance and cause actual results to differ materially from those that may be ancipated. COMPETITIVE AND REPUTATIONAL RISKS We operate in a highly compeve environment and face significant compeon and price pressure. We operate in a highly compeve industry and compete with producers, manufacturers, distributors and sales agents offering products equivalent to substanally all of the products we offer. Compeon is based on several key criteria, including product price, product performance, product quality, product availability and security of supply, breadth of product offerings, geographic reach, responsiveness of product development in cooperaon with customers, technical experse and customer service. Many of our competors are larger than we are and may have greater financial resources, more product offerings and a broader geographic reach. As a result, these competors may be able to offer a broader array of products to a larger geographic area and may be beer able than us to withstand changes in condions within our industry, changes in the prices and availability of raw materials and changes in general economic condions as well as be able to introduce innovave products that reduce demand for or the profit from our products. Addionally, competors’ pricing decisions could compel us to decrease our prices, which could adversely affect our margins and profitability. Our ability to maintain or increase our profitability would be dependent upon our ability to offset compeve decreases in the prices and margins of our products by improving producon efficiency, invesng in infrastructure to reduce freight costs, idenfying and selling higher margin products, providing higher levels of technical experse and customer service, and improving exisng products through innovaon and research and development. If we are unable to maintain our profitability or compeve posion, we could lose market share to our competors and experience reduced profitability. Our businesses expose us to potenal product liability claims and recalls, which could adversely affect our financial condion and performance. The repackaging, blending, mixing and distribuon of products by us, including chemical products and products used in food or food ingredients or with medical, pharmaceucal or dietary supplement applicaons, involve an inherent risk of exposure to product liability claims, product recalls, product seizures and related adverse publicity, including, without limitaon, claims for exposure to our products, spills or release of our products, personal injuries, food- related claims and property damage or environmental claims. A product liability claim, judgment or recall against our customers could also result in substanal and unexpected expenditures for us, affect consumer confidence in our products and divert management’s aenon from other responsibilies. Although we maintain product liability insurance, there can be no assurance that the type or level of coverage is adequate or that we will be able to connue to maintain our exisng insurance or obtain comparable insurance at a reasonable cost, if at all. A product recall or a parally or completely uninsured judgment against us could have a material adverse effect on our business, financial condion and results of operaons. Changes in our customers’ needs or failure of our products to meet customers’ specificaons could adversely affect our sales and profitability. Our products are used for a broad range of applicaons by our customers. Changes in our customers’ product needs or processes, or reducons in demand for their end products, may enable or require our customers to reduce or eliminate consumpon of the products that we provide. Customers may also find alternave materials or processes that no longer require our products. Consequently, it is important that we develop new products to replace the sales of products that mature and decline in use. Our products provide important performance aributes to our customers’ products. If our products fail to meet the customers’ specificaons or comply with applicable laws or regulaons, perform in a manner inconsistent with the customers’ expectaons or have a shorter useful life than required, a customer could seek replacement of the product or damages for costs incurred as a result of the product failure. A successful claim or series of claims against us could have a material adverse effect on our financial condion and results of operaons and could result in a loss of one or more customers. Reducons in demand for our products could adversely affect our sales and financial results and result in facility closures. 4 Adverse publicity or negave public percepon regarding parcular ingredients or products or the dietary supplement industry in general could adversely affect the financial performance of those porons of our business. Purchasing decisions made by consumers of products that contain our ingredients may be affected by adverse publicity or negave public percepon regarding parcular ingredients or products or the dietary supplement industry in general. This negave public percepon may include publicity regarding the risks, efficacy, legality or quality of parcular ingredients or products in general or of other companies or our products or ingredients specifically. Negave public percepon may also arise from regulatory invesgaons, regardless of whether those invesgaons involve us. We are highly dependent upon consumers’ percepon of the safety and quality of products that contain our ingredients as well as similar products distributed by other companies. Thus, the mere publicaon of reports asserng that such products may be harmful could have a material adverse effect on us, regardless of whether these reports are scienfically supported. Publicity related to dietary supplements or food ingredients may also result in increased regulatory scruny of our industry. Adverse publicity may have a material adverse effect on our business, financial condion, results of operaons and cash flows. Failure to adequately protect crical data and technology systems could materially affect our operaons. Informaon technology system failures, network disrupons and breaches of data security due to internal or external factors including phishing or cyber- aacks could disrupt our operaons by causing delays or cancellaon of customer orders, impede the manufacture or shipment of products or cause standard business processes to become ineffecve, resulng in the unintenonal disclosure of informaon or damage to our reputaon. While we have taken steps to address these concerns by implemenng network security and internal control measures, including employee training, comprehensive monitoring of our networks and systems, maintenance of backup and protecve systems and disaster recovery and incident response plans, our employees, systems, networks, products, facilies and services remain vulnerable to phishing aacks and cyber-assault, and, as such, there can be no assurance that a system failure, network disrupon or data security breach will not have a material adverse effect on our business, financial condion, operang results or cash flows. RISKS RELATED TO OUR INDUSTRY Fluctuaons in the prices and availability of our raw materials, which may be cyclical in nature, could have a material adverse effect on our operaons and the margins we receive on sales of our products. We experience regular and recurring fluctuaons in the pricing of our raw materials. Those fluctuaons can be significant and occur rapidly. The cyclicality of commodity markets, such as the market for causc soda, primarily results from changes in the balance between supply and demand and the level of general economic acvity. We cannot predict whether the markets for our raw materials will favorably impact or negavely impact the margins we can realize. The prices we pay for our principal chemical raw materials generally lag the market prices of the underlying raw material. The cost of inventory we have on hand, parcularly inventories of our bulk commodity chemicals where we have significant volumes stored at our facilies, generally will lag the current market pricing of such inventory. The pricing within our supply contracts generally adjusts quarterly or monthly. While we aempt to maintain compeve pricing and stable margin dollars, the potenal variance in our cost of inventory from the current market pricing can cause significant volality in our margins realized. We do not engage in futures or other derivaves contracts to hedge against fluctuaons in future prices. We may enter into sales contracts where the selling prices for our products are fixed for a period of me, exposing us to volality in raw materials prices that we acquire on a spot market or short- term contractual basis. We aempt to pass commodity pricing changes to our customers, but we may be unable to or be delayed in doing so. Our inability to pass through price increases or any limitaon or delay in our passing through price increases could adversely affect our profit margins. We are also dependent upon the availability of our raw materials. In the event that raw materials are in short supply or unavailable, raw material suppliers may extend lead mes or limit or cut off supplies. As a result, we may not be able to supply or manufacture products for some or all of our customers. Constraints on the supply or delivery of crical raw materials could disrupt our operaons and adversely affect the performance of our businesses. 5 Demand for our products is affected by general economic condions and by the cyclical nature of many of the industries we serve, which could cause significant fluctuaons in our sales volumes and results. Demand for our products is affected by general economic condions. A decline in general economic or business condions in the industries served by our customers could have a material adverse effect on our businesses. Although we sell to areas tradionally considered non-cyclical, such as water treatment, food products and health and nutrional ingredients, many of our customers are in businesses that are cyclical in nature, such as the industrial manufacturing and energy industries which include the ethanol and agriculture industries. Downturns in these industries could adversely affect our sales and our financial results by affecng demand for and pricing of our products. Our business is subject to hazards common to chemical businesses, any of which could interrupt our producon and adversely affect our results of operaons. Our business is subject to hazards common to chemical manufacturing, blending, storage, handling and transportaon, including explosions, fires, severe weather, natural disasters, mechanical failure, unscheduled downme, transportaon interrupons, traffic accidents involving our delivery vehicles, chemical spills, discharges or releases of toxic or hazardous substances or gases and other risks. These hazards could cause personal injury and loss of life, severe damage to or destrucon of property and equipment, and environmental contaminaon. In addion, the occurrence of material operang problems or the absence of personnel due to pandemics or other disasters at any of our facilies due to any of these hazards may make it impossible for us to make sales to our customers and may result in a negave public or polical reacon. Many of our facilies are near significant residenal populaons which increases the risk of negave public or polical reacon should an environmental issue occur and could lead to adverse zoning or other regulatory acons that could limit our ability to operate our business in those locaons. Accordingly, these hazards and their consequences could have a material adverse effect on our operaons as a whole, including our results of operaons and cash flows, both during and aer the period of operaonal difficules. Environmental problems at any of our facilies could result in significant unexpected costs. We are subject to federal, state and local environmental regulaons regarding the ownership of real property and the operaons conducted on real property. Under various federal, state and local laws, ordinances and regulaons, we may own or operate real property or may have arranged for the disposal or treatment of hazardous or toxic substances at a property and, therefore, may become liable for the costs of removal or remediaon of certain hazardous substances released on or in our property or disposed of by us, as well as certain other potenal costs which could relate to hazardous or toxic substances (including governmental fines and injuries to persons and property). Such liability may be imposed whether or not we knew of, or were responsible for, the presence of these hazardous or toxic substances. Further, future changes in environmental laws or regulaons may require addional investment in capital equipment or the implementaon of addional compliance programs in the future. The cost of invesgaon, remediaon or removal of such substances may be substanal. In the conduct of our operaons, we have handled and do handle materials that are considered hazardous, toxic or volale under federal, state and local laws. The accidental release of such products cannot be completely eliminated. In addion, we operate or own facilies located on or near real property that was formerly owned and operated by others. These properes may have been used in ways that involved hazardous materials. Contaminates may migrate from, within or through any such property, which may give rise to claims against us. Third pares who are responsible for contaminaon may not have funds, or may not make funds available when needed, to pay remediaon costs imposed upon us jointly with them under environmental laws and regulaons. Our Water Treatment Group and our agricultural product sales within our Industrial Group are subject to seasonality and weather condions, which could adversely affect our results of operaons. Our Water Treatment Group has historically experienced higher sales during April to September, primarily due to a seasonal increase in chemicals used by municipal water treatment facilies. Our agricultural product sales within our Industrial Group are also seasonal, primarily corresponding with the planng season. Demand in both of these areas is also affected by weather condions, as either higher or lower than normal precipitaon or temperatures may affect water usage and the ming and the amount of consumpon of our products. We cannot assure you that seasonality or fluctuang weather condions will not have a material adverse effect on our results of operaons. 6 OPERATIONAL RISKS Disrupons within our supply chain have negavely impacted, and could connue to negavely impact, our producon, financial condion and results of operaons. We have been, and could connue to be, adversely affected by disrupons within our supply chain and transportaon network. The raw materials we need are transported by truck, rail, barge or ship by third-party providers. The costs of transporng our products or necessary raw materials could be negavely affected by factors outside of our control, including rail service interrupons or rate increases, extreme weather events, tariffs, rising fuel costs and capacity constraints. Recently, the unprecedented congeson in ocean shipping has, and will connue to, adversely impact the reliability of our imported raw materials, and transport driver shortages have caused extended lead mes for domesc shipments. In addion, rail shipments have become increasingly unreliable, with significant delays in service and increased costs. Significant delays or increased costs relang to transportaon could materially affect our financial condion and results of operaons. Similar supply chain issues have impacted and could connue to impact both our suppliers and our customers. The supply of our necessary raw materials could be interrupted due to shortages of raw materials, effects of economic, polical or financial market condions on a supplier's operaons, labor disputes or weather condions affecng products or shipments, transportaon disrupons, natural disasters, outbreaks of disease, informaon system disrupons or other reasons beyond our control. Similar disrupons at our customers could reduce demand for our products, reducing our sales and profitability. Product shortages or delays in deliveries, along with other factors such as price inflaon and higher transportaon costs, have also resulted in price increases from our suppliers. We may be unable to pass these price increases on to our customers, which could erode our profit margins. These supply chain constraints, increased product costs and inflaonary pressures could connue or escalate in the future, which would have an adverse impact on our business and results of operaons. We are highly dependent upon transportaon infrastructure to ship and receive our products and delays in these shipments could adversely affect our results of operaons. Although we maintain a number of owned trucks and trailers, we rely heavily upon transportaon provided by third pares (including common carriers, barge companies, rail companies and trans-ocean cargo companies) to deliver products to us and to our customers. Our access to third-party transportaon is not guaranteed, and we may be unable to transport our products in a mely manner, or at all, in certain circumstances, or at economically aracve rates. Disrupons in transportaon are common, are oen out of our control, and can happen suddenly and without warning. Rail limitaons, such as limitaons in rail capacity, availability of railcars, workforce shortages and adverse weather condions have disrupted or delayed rail shipments in the past and could do so in the future. Barge shipments are delayed or impossible under certain circumstances, including during mes of high or low water levels, when waterways are frozen and when locks and dams are inoperable. The availability and reliability of truck transportaon has been negavely impacted by a number of factors, including limited availability of qualified drivers and equipment, and limitaons on drivers’ hours of service. The volumes handled by, and operang challenges at, ocean ports have at mes been volale and can delay the receipt of goods, or cause the cost of shipping goods to be more expensive. Our failure to ship or receive products in a mely and efficient manner could have a material adverse effect on our financial condion and results of operaons. If we are unable to retain key personnel or aract new skilled personnel, it could have an adverse impact on our businesses. Because of the specialized and technical nature of our businesses, our future performance is dependent on the connued service of, and on our ability to aract and retain, qualified management, scienfic, technical and support personnel. The unancipated departure of key members of our management team could have an adverse impact on our business. 7 We may not be able to successfully consummate future acquisions or disposions or integrate acquisions into our business, which could result in unancipated expenses and losses. As part of our business growth strategy, we have acquired businesses and may pursue acquisions in the future. Our ability to pursue this strategy will be limited by our ability to idenfy appropriate acquision candidates and our financial resources, including available cash and borrowing capacity. In addion, we may seek to divest of businesses that are underperforming or not core to our future business. The expense incurred in consummang transacons, the me it takes to integrate an acquision or our failure to integrate businesses successfully could result in unancipated expenses and losses. Furthermore, we may not be able to realize the ancipated benefits from acquisions. The process of integrang acquired operaons into our exisng operaons may result in unforeseen operang difficules and may require significant financial resources that would otherwise be available for the ongoing development or expansion of exisng operaons. The risks associated with the integraon of acquisions include potenal disrupon of our ongoing businesses and distracon of management, unforeseen claims, liabilies, adjustments, charges and write-offs, difficulty in conforming the acquired business’ standards, processes, procedures and controls with our operaons, and challenges arising from the increased scope, geographic diversity and complexity of the expanded operaons. Our businesses are subject to risks stemming from natural disasters or other extraordinary events outside of our control, which could interrupt our producon and adversely affect our results of operaons. Natural disasters have the potenal of interrupng our operaons and damaging our properes, which could adversely affect our businesses. Flooding of the Mississippi River has temporarily shied the Company’s terminal operaons out of its buildings four mes since the spring of 2010, including most recently the spring of 2019. We can give no assurance that flooding or other natural disasters will not recur or that there will not be material damage or interrupon to our operaons in the future from such disasters. Chemical-related assets may be at greater risk of future terrorist aacks than other possible targets in the United States. Federal law imposes site security requirements, specifically on chemical facilies, which have increased our overhead expenses. Federal regulaons have also been adopted to increase the security of the transportaon of hazardous chemicals in the United States. We ship and receive materials that are classified as hazardous and we believe we have met these requirements, but addional federal and local regulaons that limit the distribuon of hazardous materials are being considered. Bans on movement of hazardous materials through certain cies could adversely affect the efficiency of our logiscal operaons. Broader restricons on hazardous material movements could lead to addional investment and could change where and what products we provide. The occurrence of extraordinary events, including future terrorist aacks, wars, global health developments and pandemics (including the COVID-19 outbreak), or escalaon of hoslies, cannot be predicted, but their occurrence can be expected to negavely affect the economy in general, and specifically the markets for our products. The resulng damage from a direct aack on our assets, or assets used by us, could include loss of life and property damage. In addion, available insurance coverage may not be sufficient to cover all of the damage incurred or, if available, may be prohibively expensive. We may not be able to renew our leases of land where four of our operaons facilies reside. We lease the land where our three main terminals are located and where another significant manufacturing plant is located. These leases, including all renewal periods, have expiraon dates from 2023 to 2044. The failure to secure extended lease terms on any one of these facilies may have a material adverse impact on our business, as they are where a poron of our chemicals are manufactured and where the majority of our bulk chemicals are stored. While we can make no assurances, based on historical experience and ancipated future needs, we intend to extend these leases and believe that we will be able to renew our leases as the renewal periods expire. If we are unable to renew three of our leases (two relate to terminals and one to manufacturing) any property remaining on the land becomes the property of the lessor, and the lessor has the opon to either maintain the property or remove the property at our expense. The fourth lease provides that we turn any property remaining on the land over to the lessor for them to maintain or remove at their expense. The cost to relocate our operaons could have a material adverse effect on our results of operaons and financial condion. 8 LEGAL AND REGULATORY RISKS Environmental, health and safety, transportaon and storage laws and regulaons cause us to incur substanal costs and may subject us to future liabilies and risks. We are subject to numerous federal, state and local environmental, health and safety laws and regulaons in the jurisdicons in which we operate, including the management, storage, transportaon and disposal of chemicals and wastes; product regulaon; air water and soil contaminaon; and the invesgaon and cleanup of any spills or releases that may result from our management, handling, storage, sale, or transportaon of chemicals and other products. The nature of our business exposes us to risks of liability under these laws and regulaons. Ongoing compliance with such laws and regulaons is an important consideraon for us and we invest substanal capital and incur significant operang costs in our compliance efforts. In addion, societal concerns regarding the safety of chemicals in commerce and their potenal impact on the environment have resulted in a growing trend towards increasing levels of product safety and environmental protecon regulaons. These concerns have led to, and could connue to result in, more stringent regulatory intervenon by governmental authories. In addion, these concerns could influence public percepons, impact the commercial viability of the products we sell and increase the costs to comply with increasingly complex regulaons, which could have a negave impact on our business, financial condion and results of operaons. In addion, we operate a fleet of more than 200 commercial vehicles, primarily in our Water Treatment Group, which are highly regulated, including by the U.S. Department of Transportaon (“DOT”). The DOT governs transportaon maers including authorizaon to engage in motor carrier service, including the necessary permits to conduct our businesses, equipment operaon, and safety. We are audited periodically by the DOT to ensure that we are in compliance with various safety, hours-of-service, and other rules and regulaons. If we were found to be out of compliance, the DOT could severely restrict or otherwise impact our operaons, which could have a material adverse effect on our operaons as a whole, including our results of operaons and cash flows. If we violate applicable laws or regulaons, in addion to being required to correct such violaons, we could be held liable in administrave, civil or criminal proceedings for substanal fines and other sancons that could disrupt, limit or halt our operaons, which could have a material adverse effect on our operaons as a whole, including our results of operaons and cash flows. Liabilies associated with the invesgaon and cleanup of releases of hazardous substances, as well as personal injury, property damages or natural resource damages arising out of such releases of hazardous substances, may be imposed in many situaons without regard to violaons of laws or regulaons or other fault, and may also be imposed jointly and severally (so that a responsible party may be held liable for more than its share of the losses involved, or even the enre loss). Such liabilies can be difficult to idenfy and the extent of any such liabilies can be difficult to predict. We use, and in the past have used, hazardous substances at many of our facilies, and have generated, and connue to generate, hazardous wastes at a number of our facilies. We have in the past been, and may in the future be, subject to claims relang to exposure to hazardous materials and the associated liabilies may be material. 9 Our food, pharmaceucal and health and nutrion products are subject to government regulaon, both in the United States and abroad, which could increase our costs significantly and limit or prevent the sale of such products. The manufacture, packaging, labeling, adversing, promoon, distribuon and sale of our food, pharmaceucal pescide and health and nutrion products are subject to regulaon by numerous naonal and local governmental agencies in the United States and other countries. The primary regulatory bodies in the United States are the Food and Drug Administraon (the “FDA”), the Environmental Protecon Agency, the United States Department of Agriculture and the Federal Trade Commission, and we are also subject to similar regulators in other countries. Failure to comply with these regulatory requirements may result in various types of penales or fines. These include injuncons, product withdrawals, recalls, product seizures, fines and criminal prosecuons. Individual states also regulate our products. A state may interpret claims or products presumpvely valid under federal law as illegal under that state’s regulaons. Approvals or licensing may be condioned on reformulaon of products or may be unavailable with respect to certain products or product ingredients. Any of these government agencies, as well as legislave bodies, can change exisng regulaons, or impose new ones, or could take aggressive measures, causing or contribung to a variety of negave consequences, including: requirements for the reformulaon of certain or all products to meet new standards, • stopping the sale of products, • • the recall or disconnuance of certain or all products, • addional record-keeping requirements, • expanded documentaon of the properes of certain or all products, • expanded or different labeling, • adverse event tracking and reporng, and • addional scienfic substanaon. In parcular, the FDA’s current GMPs describe policies and procedures designed to ensure that nutraceucals, pharmaceucals and dietary supplements are produced in a quality manner, do not contain contaminants or impuries, and are accurately labeled and cover the manufacturing, packaging, labeling and storing of supplements, with requirements for quality control, design and construcon of manufacturing plants, tesng of ingredients and final products, record keeping, and complaints processes. Those who manufacture, package or store dietary supplements must comply with current GMPs. If we or our suppliers fail to comply with current GMPs, the FDA may take enforcement acon against us or our suppliers. Any or all of the potenal negave consequences described above could have a material adverse effect on us or substanally increase the cost of doing business in these areas. There can be no assurance that the regulatory environment in which we operate will not change or that such regulatory environment, or any specific acon taken against us, will not result in a material adverse effect on us. 10 FINANCIAL RISKS The insurance that we maintain may not fully cover all potenal exposures. We maintain lines of commercial insurance, such as property, general liability and casualty insurance, but such insurance may not cover all risks associated with the hazards of our businesses and is subject to limitaons, including deducbles and limits on the liabilies covered. We may incur losses beyond the limits or outside the coverage of our insurance policies, including liabilies for environmental remediaon and product liability. In addion, from me to me, various types of insurance for companies in the chemical, food or health and nutrion products industries have not been available on commercially acceptable terms or, in some cases, have not been available at all. In the future, we may not be able to obtain coverage at current levels, and our premiums may increase significantly on coverage that we maintain. Failure to comply with the covenants under our credit facility may have a material adverse effect. We are party to a credit agreement (the “Credit Agreement”) with U.S. Bank Naonal Associaon and other lenders (collecvely, the “Lenders”), which includes secured revolving credit facilies (the “Revolving Loan Facility”) totaling $250.0 million. The Revolving Loan Facility includes a $10.0 million leer of credit subfacility and $25.0 million swingline subfacility. At April 3, 2022, we had $126.0 million outstanding under the Revolving Loan Facility. We may make payments on the Revolving Loan Facility from me to me. If we are unable to generate sufficient cash flow or otherwise obtain funds necessary to make payments on our credit facilies, we could be in default when the facilies become due in 2027. We are also required to comply with several financial covenants under the Credit Agreement. Our ability to comply with these financial covenants may be affected by events beyond our control, which could result in a default under the Credit Agreement; such default may have a material adverse effect on our business, financial condion, operang results or cash flows. The Credit Agreement also contains other customary affirmave and negave covenants, including covenants that restrict our ability to incur addional indebtedness, dispose of significant assets, make certain investments, including any acquisions other than permied acquisions, make certain payments, enter into sale and leaseback transacons, grant liens on its assets or rate management transacons, subject to certain limitaons. These restricons may adversely affect our business. Impairment to the carrying value of our goodwill or other intangible assets could adversely affect our financial condion and consolidated results of operaons. Goodwill represents the excess of the cost of acquired businesses over the fair value of idenfiable tangible net assets and idenfiable intangible assets purchased. Goodwill is tested at least annually for impairment and is tested for impairment more frequently if events or changes in circumstances indicate that the asset might be impaired. A significant amount of judgment is involved in determining if an indicaon of impairment exists. Factors may include, among others: a significant decline in our expected future cash flows; a sustained, significant decline in our stock price and market capitalizaon; a significant adverse change in the business climate; unancipated compeon; and slower growth rates. An adverse change in these factors may have a significant impact on the recoverability of the net assets recorded, and any resulng impairment charge in the future could have a material adverse effect on our financial condion and consolidated results of operaons. We evaluate the useful lives of our intangible assets to determine if they are definite- or indefinite-lived. Reaching a determinaon on useful life requires significant judgments and assumpons regarding the future effects of obsolescence, demand, compeon, other economic factors (such as the stability of the industry, legislave acon that results in an uncertain or changing regulatory environment, and expected changes in distribuon channels), and the expected lives of other related groups of assets. We cannot accurately predict the amount and ming of any impairment of goodwill and other intangible assets. Should the value of these assets become impaired, there could be a material adverse effect on our financial condion and consolidated results of operaons. ITEM 1B. UNRESOLVED STAFF COMMENTS None. 11 ITEM 2. PROPERTIES Our facilies material to our operaons consist of our locaons described below. In addion to the facilies listed below, our Water Treatment group operates out of 33 addional warehouse locaons, the majority of which are owned by us. We believe that our facilies are adequate and suitable for the purposes they serve. Unless noted, each facility is owned by us and is primarily used as office and warehouse space. We believe that we carry customary levels of insurance covering the replacement of damaged property. Group Corporate headquarters Health and Nutrion Industrial Industrial and Water Treatment Water Treatment Locaon Roseville, MN Fullerton, CA (1) Florida, NY (2) Minneapolis, MN (3) Centralia, IL (4) Dupo, IL (5) St. Paul, MN (6) Rosemount, MN (7) St. Paul, MN (8) Camanche, IA Memphis, TN Apopka, FL Approx. Square Feet 50,000 55,800 107,000 177,000 77,000 64,000 32,000 105,000 59,000 95,000 41,000 32,100 (1) This is a leased facility comprising administrave offices and a distribuon facility. The lease runs through January 2026. (2) This is comprised of (i) a 79,000 square foot manufacturing plant which sits on approximately 16 acres and (ii) a leased 28,000 square foot warehouse located in close proximity that is leased unl December 2022. (3) This manufacturing locaon sits on approximately 11 acres of land. (4) This manufacturing facility includes 12 acres of land owned by the Company. (5) The land for this manufacturing and packaging facility is leased from a third party, with the lease expiring in May 2023. (6) These terminal operaons, located at two sites on opposite sides of the Mississippi River, are made up of three buildings, outside storage tanks for the storage of liquid bulk chemicals, including causc soda, as well as numerous smaller tanks for storing and mixing chemicals. The land is leased from the Port Authority of the City of St. Paul, Minnesota. One of the applicable leases runs through 2033, while the other one runs through 2044 including all available lease extensions. (7) This includes two adjacent facilies comprising a total of 56 acres of land owned by the Company. These manufacturing facilies have outside storage tanks for the storage of bulk chemicals, as well as numerous smaller tanks for storing and mixing chemicals. (8) This facility, which consists of a 59,000 square-foot building located on approximately 10 acres of land, has outside storage capacity for liquid bulk chemicals, as well as numerous smaller tanks for storing and mixing chemicals. The land is leased from the Port Authority of the City of St. Paul, Minnesota and runs unl 2029. ITEM 3. LEGAL PROCEEDINGS There are no material pending legal proceedings, other than ordinary roune ligaon incidental to the business, to which we or any of our subsidiaries are a party or of which any of our property is the subject. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. 12 PART II ITEM 5. MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Our common shares are listed on the Nasdaq Global Select Market under the symbol “HWKN.” As of May 13, 2022, shares of our common shares were held by approximately 387 shareholders of record. The following graph compares the cumulave total shareholder return on our common shares with the cumulave total returns of the Nasdaq Industrial Index, the Nasdaq Composite Index, the Russell 2000 Index and the Standard & Poor’s (“S&P”) Small Cap 600 Index for our last five completed fiscal years. The graph assumes the investment of $100 in our stock and each of those indices on April 2, 2017, and reinvestment of all dividends. 13 ITEM 6. RESERVED ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following is a discussion and analysis of our financial condion and results of operaons for fiscal 2022 and 2021. This discussion should be read in conjuncon with the Consolidated Financial Statements and Notes to Consolidated Financial Statements included in Item 8 of this Annual Report on Form 10- K. We have omied discussion of the earliest of the three years covered by our consolidated financial statements presented in this report because that disclosure was already included in our Annual Report on Form 10-K for fiscal 2021, filed with the SEC on June 2, 2021. You are encouraged to reference Part II, Item 7, within that report, for a discussion of our financial condion and results of operaons for fiscal 2020 compared to fiscal 2021. Overview We derive substanally all of our revenues from the sale of specialty chemicals and ingredients that we formulate, distribute, blend and manufacture for our Industrial, Water Treatment and Health and Nutrion customers. Financial Overview Highlights of fiscal 2022 include: • • • Sales of $774.5 million, a 30% increase from fiscal 2021; Gross profit of $146.5 million, an increase of $22.8 million, or 18% from fiscal 2021; An increase in selling, general and administrave (“SG&A”) expenses of $7.4 million year over year, but a decrease of 160 basis points as a percentage of sales when compared to fiscal 2021; We focus on total profitability dollars when evaluang our financial results as opposed to profitability as a percentage of sales, as sales dollars tend to fluctuate as raw material prices rise and fall, parcularly in our Industrial and Water Treatment segments. The costs for certain of our raw materials can rise or fall rapidly, causing fluctuaons in gross profit as a percentage of sales. We use the last in, first out (“LIFO”) method of valuing the majority of our inventory in our Industrial and Water Treatment segments, which causes the most recent product costs to be recognized in our income statement. The LIFO inventory valuaon method and the resulng cost of sales are consistent with our business pracces of pricing to current chemical raw material prices. Inventories in our Health and Nutrion segment are valued using the first-in, first-out (“FIFO”) method. We disclose the sales of our bulk commodity products as a percentage of total sales dollars for our Industrial and Water Treatment segments. Our definion of bulk commodity products includes products that we do not modify in any way, but receive, store, and ship from our facilies, or direct ship to our customers in large quanes. Business and Property Acquisions On December 30, 2021, we acquired substanally all the assets of NAPCO Chemical Company, Inc. and its affiliates ("NAPCO") under the terms of an asset purchase agreement among us, NAPCO and certain other pares thereto. NAPCO manufactures and distributes water treatment chemicals from three locaons in Texas. The results of operaons are included as part of our Water Treatment segment from the date of acquision forward. On October 29, 2021, we acquired substanally all the assets of Water and Waste Speciales, LLC, under the terms of an asset purchase agreement with Water and Waste Speciales and its shareholders. Water and Waste Speciales was a water treatment chemical distribuon company operang primarily in Alabama. The results of operaons since the acquision date are included in our Water Treatment segment. 14 On September 20, 2021, we acquired substanally all the assets of Southeast Water Systems LLC, under the terms of an asset purchase agreement with Southeast Water Systems and its shareholders. Southeast Water Systems supplied and installed water treatment chemical equipment to its customers located primarily in Alabama, southern Georgia and the Florida panhandle. The results of operaons since the acquision date are included in our Water Treatment segment. In the fourth quarter of fiscal 2021, we acquired substanally all the assets of C & L Aqua Professionals, Inc. and LC Blending, Inc. (together, “C&L Aqua”) under the terms of an asset purchase agreement among us, C&L Aqua and its shareholders. C&L Aqua was a water treatment chemical distribuon company operang primarily in Louisiana. The results of operaons since the acquision date are included in our Water Treatment segment. In the third quarter of fiscal 2021, we acquired a manufacturing facility to allow further expansion and growth in both our Industrial and Water Treatment segments. This site is adjacent to our facility in Rosemount, Minnesota, adding 40,000 square feet of manufacturing and warehouse space on 28 acres of land to bring us to a total of 105,000 square feet of space on 56 acres of land, with rail access at both of the sites. The expansion will allow for future growth and provide supply chain flexibility on certain raw materials to beer serve our customers. In the second quarter of fiscal 2021, we acquired substanally all the assets of American Development Corporaon of Tennessee, Inc. (“ADC”) under the terms of an asset purchase agreement among us, ADC and its shareholders. ADC was a water treatment chemical distribuon company operang primarily in Tennessee, Georgia and Kentucky. The results of operaons since the acquision date are included in our Water Treatment segment. The aggregate annual revenue of the three businesses acquired in fiscal 2022 totaled approximately $17 million, as determined using the applicable twelve- month period preceding each respecve acquision date. The aggregate annual revenue from the fiscal 2021 acquisions totaled approximately $25 million, as determined using the applicable twelve-month period preceding each respecve acquision date. Stock Split On March 1, 2021, we effected a two-for-one split of our common stock and adjusted the par value from $.05 per share to $0.01 per share. At the same me, we increased the number of authorized shares from 30 million to 60 million. Our consolidated financial statements, related notes, and other financial data contained in this report have been adjusted to give retroacve effect to the stock split for all periods presented. Statement on COVID-19 During the pandemic caused by COVID-19, federal, state and local governments around the world implemented stringent measures to help control the spread of the virus, including, from me to me, quarannes, “shelter in place” and “stay at home” orders, travel restricons or bans, business curtailments, school closures, and other protecve measures. While most restricons have eased since the start of the COVID-19 pandemic, certain restricons remain in place or new restricons may be implemented in the future. All of our manufacturing facilies have qualified as essenal operaons (or the equivalent) under applicable federal and state orders. As a result, all of our manufacturing sites and facilies have connued to operate, with no significant impact to our output levels. During the public health crisis, we remained focused on the health and safety of our employees, customers and suppliers and maintaining safe and reliable operaons of our manufacturing sites. As our operaons and products are essenal to crical naonal infrastructure, it is imperave that we connue to supply materials including the products needed to maintain safe drinking water, ingredients essenal for large-scale food, pharmaceucal and other health product manufacturing and nutrion products needed to support our country's crical infrastructure. 15 Results of Operaons The following table sets forth certain items from our statement of income as a percentage of sales for fiscal 2022 and 2021: Fiscal 2022 Fiscal 2021 Sales Cost of sales Gross profit Selling, general and administrave expenses Operang income Interest expense, net Other income Income before income taxes Income tax provision Net income Fiscal 2022 Compared to Fiscal 2021 Sales 100.0 % (81.1)% 18.9 % (9.7)% 9.2 % (0.2)% — % 9.0 % (2.3)% 6.7 % 100.0 % (79.3)% 20.7 % (11.3)% 9.4 % (0.2)% 0.2 % 9.4 % (2.5)% 6.9 % Sales were $774.5 million for fiscal 2022, an increase of $177.7 million, or 30%, from sales of $596.9 million for fiscal 2021. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $17.5 million in addional sales. Industrial Segment. Industrial segment sales increased $113.6 million, or 42%, to $386.9 million for fiscal 2022, as compared to $273.4 million for fiscal 2021. Sales of bulk commodity products in the Industrial segment were approximately 16% of sales dollars in fiscal 2022 and 14% of sales dollars in fiscal 2021. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $10.0 million in addional sales in our Industrial segment. In addion, the increase in sales was driven by increased selling prices on many of our products driven by higher costs on many of our raw materials, as well as increased sales of our bulk and our manufactured, blended and repackaged products. Water Treatment Segment. Water Treatment segment sales increased $58.1 million, or 34%, to $228.1 million for fiscal 2022, as compared to $170.0 million for fiscal 2021. Sales of bulk commodity products in the Water Treatment segment were approximately 9% of sales dollars in both fiscal 2022 and fiscal 2021. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $3.9 million in addional sales in our Water Treatment segment. In addion, sales increased as a result of increased demand for our products as well as the added sales from acquisions. Health and Nutrion Segment. Health and Nutrion segment sales increased $6.0 million, or 4%, to $159.5 million for fiscal 2022, as compared to $153.5 million for fiscal 2021. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $3.6 million in addional sales in our Health and Nutrion segment. In addion, sales increased as a result of an increase in sales of our specialty distributed products, which was parally offset by the normalizing of demand for our manufactured products when compared to the temporary COVID-driven increase in demand these products experienced in the prior year. Gross Profit Gross profit increased $22.8 million, or 18%, to $146.5 million, or 19% of sales, for fiscal 2022, from $123.8 million, or 21% of sales, for fiscal 2021. During fiscal 2022, the LIFO reserve increased, and gross profits decreased, by $15.8 million, primarily due to rising input costs. In fiscal 2021, the LIFO reserve decreased, and gross profits increased, by $0.1 million. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $3.6 million in addional gross profit. 16 Industrial Segment. Gross profit for the Industrial segment increased $16.3 million, or 38%, to $59.6 million, or 15% of sales, for fiscal 2022, from $43.3 million, or 16% of sales, for fiscal 2021. During fiscal 2022, the LIFO reserve increased, and gross profits decreased, by $10.4 million, primarily due to rising raw material costs. In fiscal 2021, the LIFO reserve decreased, and gross profits increased, by $0.2 million. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $1.9 million in addional gross profit in our Industrial segment. In addion, gross profit increased as a result of the increase in sales, parally offset by the negave impact resulng from the increase in the LIFO reserve. Water Treatment Segment. Gross profit for the Water Treatment segment increased $7.8 million, or 17%, to $54.6 million, or 24% of sales, for fiscal 2022, from $46.8 million, or 28% of sales, for fiscal 2021. During fiscal 2022, the LIFO reserve increased, and gross profits decreased, by $5.4 million, primarily due to rising raw material costs. During fiscal 2021, the LIFO reserve increased, and gross profit decreased, by $0.1 million. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $1.0 million in addional gross profit in our Water Treatment segment. In addion, gross profit increased as a result of the increase in sales. Health and Nutrion Segment. Gross profit for our Health and Nutrion segment decreased $1.3 million, or 4%, to $32.3 million, or 20% of sales, for fiscal 2022, from $33.6 million, or 22% of sales, for fiscal 2021. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $0.7 million in addional gross profit in our Health and Nutrion segment. This increase from the 53rd week was more than offset by a decrease in gross profit resulng from a decline in sales of our manufactured products which generally have higher per-unit margins than our specialty distributed products. Selling, General and Administrave Expenses SG&A expenses increased $7.4 million to $75.3 million, or 10% of sales, for fiscal 2022, from $67.9 million, or 11% of sales, for fiscal 2021. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $1.0 million in addional SG&A expense. In addion, expenses increased in part due to the added costs from the acquired businesses in the Water Treatment segment, an increase in variable incenve compensaon, increased costs due to added personnel and other resources as we invest to grow the business, and normalizaon of travel and other variable expenses to pre-COVID levels. Operang Income Operang income was $71.2 million, or 9% of sales, for fiscal 2022, as compared to $55.9 million, or 9% of sales, for fiscal 2021 due to the combined impact of the factors discussed above. We esmated the impact of the 53rd week in fiscal 2022 to be approximately $3 million in addional operang income. Interest Expense, Net Interest expense was $1.4 million for fiscal 2022, a decrease of $0.1 million from interest expense of $1.5 million for fiscal 2021. Lower borrowing rates compared to the prior year more than offset the increase in outstanding borrowings in the current year. Income Tax Provision Our effecve tax rate was approximately 26.5% for both fiscal 2022 and fiscal 2021. The effecve tax rate is impacted by projected levels of annual taxable income, permanent items, and state taxes. 17 Selected Quarterly Financial Data Selected financial data for our fiscal quarters is shown below. No changes have been made to previously reported informaon. (In thousands, except per share data) Sales Gross profit Selling, general, and administrave expenses Operang income Net income Basic earnings per share Diluted earnings per share Sales Gross profit Selling, general, and administrave expenses Operang income Net income Basic earnings per share Diluted earnings per share Sales Gross profit Selling, general, and administrave expenses Operang income Net income Basic earnings per share Diluted earnings per share $ $ $ $ $ $ $ $ $ First Second Fiscal 2022 Third Fourth Total 181,241 $ 38,974 16,856 22,118 16,628 0.79 $ 0.79 $ 183,277 $ 37,287 17,679 19,608 14,133 0.67 $ 0.67 $ 187,050 $ 33,940 19,681 14,259 10,204 0.49 $ 0.48 $ 222,973 $ 36,319 21,110 15,209 10,577 0.51 $ 0.50 $ First Second Fiscal 2021 Third Fourth 143,172 $ 30,976 15,038 15,938 11,788 0.56 $ 0.55 $ 147,801 $ 32,797 16,221 16,576 12,190 0.58 $ 0.57 $ 142,927 $ 28,239 17,750 10,489 7,921 0.38 $ 0.37 $ 162,971 $ 31,750 18,875 12,875 9,081 0.43 $ 0.43 $ First Second Fiscal 2020 Third Fourth 147,336 $ 28,797 14,836 13,961 9,807 0.46 $ 0.46 $ 140,043 $ 27,994 14,817 13,177 9,250 0.44 $ 0.43 $ 120,406 $ 21,478 14,702 6,776 4,547 0.22 $ 0.21 $ 132,413 $ 22,648 14,891 7,757 4,763 0.23 $ 0.22 $ 774,541 146,520 75,326 71,194 51,542 2.46 2.44 596,871 123,762 67,884 55,878 40,980 1.95 1.93 540,198 100,917 59,246 41,671 28,367 1.34 1.33 Earnings per share may not equal the face of the Consolidated Statements of Income due to rounding. Liquidity and Capital Resources Cash provided by operang acvies in fiscal 2022 was $42.8 million compared to $43.8 million in fiscal 2021. The decrease in cash provided by operang acvies in fiscal 2022 as compared to fiscal 2021 was driven by higher inventory levels and increases in customer receivables resulng from higher sales, mostly offset by an increase in net income and accounts payable. The inventory increase was driven by increased raw material costs as well as a conscious management decision to increase inventory levels due to increased customer demand and supply chain issues. Due to the nature of our operaons, which includes purchases of large quanes of bulk chemicals, the ming of purchases can result in significant changes in working capital and the resulng operang cash flow. Historically, our cash requirements for working capital increase during the period from March through November as causc soda inventory levels increase as most of our barges are received during this period. 18 Cash used in invesng acvies was $49.8 million in fiscal 2022 compared to $71.4 million in fiscal 2021. Capital expenditures were $28.5 million in fiscal 2022 and $20.8 million in fiscal 2021. Total cash used in invesng acvies in fiscal 2022 included an aggregate of $21.5 million for Water Treatment group acquisions compared to $51.0 million in Water Treatment group acquision spending in fiscal 2021. Capital expenditures in fiscal 2022 included vehicles and trucks, facility improvements, and pharmaceucal ingredient manufacturing capabilies, along with other new and replacement equipment. Capital expenditures in fiscal 2021 included pharmaceucal ingredient manufacturing capabilies, vehicles and trucks, and the purchase of a previously leased Water Treatment branch facility, along with other new and replacement equipment. Cash provided by financing acvies was $7.4 million in fiscal 2022, as compared to $26.4 million in fiscal 2021. Cash provided by financing acvies included net debt borrowings of $27.0 million in fiscal 2022, compared to net debt borrowings of $39.0 million in fiscal 2021, which was used primarily to fund our acquisions in both fiscal years. We paid out cash dividends of $11.1 million in fiscal 2022 and $10.0 million in fiscal 2021. In fiscal 2022, we used $8.5 million to repurchase shares under our board-authorized share repurchase program, and in fiscal 2021, we used $4.1 million to repurchase shares under the program. Our cash balance was $3.5 million at April 3, 2022, an increase of $0.5 million as compared with March 28, 2021. Cash flows generated by operaons and financing acvies during fiscal 2022 were offset by the cash expended for acquisions in fiscal 2022, capital expenditures and dividend payments. We were party to an amended and restated credit agreement (the “Prior Credit Agreement”) with U.S. Bank as Sole Lead Arranger and Sole Book Runner, and other lenders from me to me party thereto (collecvely, the “Lenders”), whereby U.S. Bank was also serving as Administrave Agent. The Prior Credit Agreement provided us with senior secured revolving credit facilies (the “Prior Revolving Loan Facility”) totaling $150.0 million. The Prior Revolving Loan Facility included a $5.0 million leer of credit subfacility and $15.0 million swingline subfacility. The Prior Revolving Loan Facility was scheduled to terminate on November 30, 2023, and was secured by substanally all of our personal property assets and those of our subsidiaries. On March 31, 2022, we entered into a second amended and restated credit agreement (the “Credit Agreement”) with U.S. Bank Naonal Associaon (“U.S. Bank”) as Sole Lead Arranger and Sole Book Runner, and other lenders from me to me party thereto (collecvely, the “Lenders”), whereby U.S. Bank is also serving as Administrave Agent. The Credit Agreement refinanced the revolving loan under our previous credit agreement with U.S. Bank and provides us with senior secured revolving credit facilies (the “Revolving Loan Facility”) totaling $250 million. The Revolving Loan Facility includes a $10 million leer of credit subfacility and $25 million swingline subfacility. The Revolving Loan Facility has a five-year maturity date, maturing on April 30, 2027. The Revolving Loan Facility is secured by substanally all of our personal property assets and those of our subsidiaries. We used $126.0 million of the proceeds from the Revolving Loan Facility to refinance the obligaons under the previous credit facility. We may use the remaining amount of the Revolving Loan Facility for working capital, capital expenditures, share repurchases, restricted payments and acquisions permied under the Credit Agreement, and other general corporate purposes. Borrowings under the Revolving Loan Facility bear interest at a rate per annum equal to one of the following, plus, in both cases, an applicable margin based upon our leverage rao: (a) Term SOFR, which includes a credit spread adjustment of 0.10%, for an interest period of one, three or six months as selected by us, reset at the end of the selected interest period, or (b) a base rate determined by reference to the highest of (1) U. S. Bank’s prime rate, (2) the Federal Funds Effecve Rate plus 0.5%, or (3) one-month Term SOFR for U.S. dollars plus 1.0%. The Term SOFR margin is between 0.85% and 1.35%, depending on our leverage rao. The base rate margin is between 0.00% and 0.35%, depending on our leverage rao. At April 3, 2022, the effecve interest rate on our borrowings was 1.2%. In addion to paying interest on the outstanding principal under the Revolving Loan Facility, we are required to pay a commitment fee on the unulized commitments thereunder. The commitment fee is between 0.15% and 0.25%, depending on our leverage rao. Debt issuance costs paid to the Lenders are being amorzed as interest expense over the term of the Credit Agreement. As of April 3, 2022, the unamorzed balance of these costs was $0.4 million, and is reflected as a reducon of debt on our balance sheet. 19 The Credit Agreement requires us to maintain (a) a minimum fixed charge coverage rao of 1.15 to 1.00 and (b) a maximum total cash flow leverage rao of 3.0 to 1.0. The Credit Agreement also contains other customary affirmave and negave covenants, including covenants that restrict our ability to incur addional indebtedness, dispose of significant assets, make certain investments, including any acquisions other than permied acquisions, make certain payments, enter into sale and leaseback transacons, grant liens on our assets or enter into rate management transacons, subject to certain limitaons. We are permied to make distribuons, pay dividends and repurchase shares so long as no default or event of default exists or would exist as a result thereof. We were in compliance with all covenants of the Credit Agreement as of April 3, 2022 and expect to remain in compliance with all covenants for the next 12 months. The Credit Agreement contains customary events of default, including failure to comply with covenants in the Credit Agreement and other loan documents, cross default to other material indebtedness, failure by us to pay or discharge material judgments, bankruptcy, and change of control. The occurrence of an event of default would permit the lenders to terminate their commitments and accelerate loans under the Credit Facility. We have in place an interest rate swap agreement to manage the risk associated with a poron of our variable-rate long-term debt. We do not ulize derivave instruments for speculave purposes. The interest rate swap involves the exchange of fixed-rate and variable-rate payments without the exchange of the underlying noonal amount on which the interest payments are calculated. The noonal amount of the swap agreement is $60 million and it will terminate on May 1, 2027. As part of our growth strategy, we have acquired businesses and may pursue acquisions or other strategic relaonships in the future that we believe will complement or expand our exisng businesses or increase our customer base. We believe we could borrow addional funds under our current or new credit facilies or sell equity for strategic reasons or to further strengthen our financial posion. Contractual Obligaons and Commercial Commitments The following table provides aggregate informaon about our contractual payment obligaons and the periods in which payments are due: Payments Due by Fiscal Period Contractual Obligaon 2023 2024 2025 2026 2027 More than 5 Years Total (In thousands) Senior secured revolver (1) Interest payments (2) Operang lease obligaons (3) Pension withdrawal liability (4) $ $ $ $ — $ 1,833 $ 1,889 $ 467 $ — $ 1,833 $ 1,515 $ 467 $ — $ 1,833 $ 1,450 $ 467 $ — $ 1,833 $ 1,388 $ 467 $ — $ 1,833 $ 1,359 $ 467 $ 126,000 $ 152 $ 5,171 $ 3,037 $ 126,000 9,317 12,772 5,372 (1) Represents balance outstanding as of April 3, 2022, and assumes such amount remains outstanding unl its maturity date, as periodic payments are not required under the terms of our Credit Agreement. However, it is our intenon to pay down our debt with available excess cash flow. See Note 9 of our consolidated Financial Statements for further informaon. (2) Represents interest payments and commitment fees payable on outstanding balances under our revolver, and assumes interest rates remain unchanged from the rate as of April 3, 2022. (3) As reported under ASC Topic 842 (4) This relates to our withdrawal from a mulemployer pension plan. Payments on this obligaon will connue through 2034. Crical Accounng Esmates In preparing the financial statements, we follow U.S. generally accepted accounng principles (“GAAP”). The preparaon of these financial statements requires us to make esmates and judgments that affect the reported amounts of assets, liabilies, sales and expenses, and related disclosure of conngent assets and liabilies. We re-evaluate our esmates on an on-going basis. Our esmates are based on historical experience and on various other assumpons that are believed to be reasonable under the circumstances. Actual results may differ from these esmates under different assumpons and condions. We have determined we have no crical accounng esmates material to our consolidated financial posion, results of operaons or cash flow. 20 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK We are subject to the risk inherent in the cyclical nature of commodity chemical prices. However, we do not currently purchase forward contracts or otherwise engage in hedging acvies with respect to the purchase of commodity chemicals. We aempt to pass changes in the cost of our materials on to our customers; however, there are no assurances that we will be able to pass on the increases in the future. We are exposed to market risks related to interest rates. Our exposure to changes in interest rates is limited to borrowings under our credit facility. A 25-basis point change in interest rates on the variable-rate poron of debt not covered by the interest rate swap would potenally increase or decrease annual interest expense by approximately $0.3 million. Other types of market risk, such as foreign currency risk, do not arise in the normal course of our business acvies. 21 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Report of Independent Registered Public Accounng Firm (PCAOB ID: 248) Report of Independent Registered Public Accounng Firm (PCAOB ID: 185) Index to Consolidated Financial Statements Consolidated Balance Sheets Consolidated Statements of Income Consolidated Statements of Comprehensive Income Consolidated Statements of Shareholders’ Equity Consolidated Statements of Cash Flows Notes to Consolidated Financial Statements 22 23 25 26 27 28 29 30 31 Board of Directors and Shareholders Hawkins, Inc. Report of Independent Registered Public Accounng Firm Opinion on internal control over financial reporng We have audited the internal control over financial reporng of Hawkins, Inc. (a Minnesota corporaon) and subsidiaries (the “Company”) as of April 3, 2022, based on criteria established in the 2013 Internal Control—Integrated Framework issued by the Commiee of Sponsoring Organizaons of the Treadway Commission (“COSO”). In our opinion, the Company maintained, in all material respects, effecve internal control over financial reporng as of April 3, 2022, based on criteria established in the 2013 Internal Control—Integrated Framework issued by COSO. We also have audited, in accordance with the standards of the Public Company Accounng Oversight Board (United States) (“PCAOB”), the consolidated financial statements of the Company as of and for the year ended April 3, 2022, and our report dated May 18, 2022 expressed an unqualified opinion on those financial statements. Basis for opinion The Company’s management is responsible for maintaining effecve internal control over financial reporng and for its assessment of the effecveness of internal control over financial reporng, included in the accompanying Management’s Report on Internal Control Over Financial Reporng (“Management’s Report”). Our responsibility is to express an opinion on the Company’s internal control over financial reporng based on our audit. We are a public accounng firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securies laws and the applicable rules and regulaons of the Securies and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effecve internal control over financial reporng was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporng, assessing the risk that a material weakness exists, tesng and evaluang the design and operang effecveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. Our audit of, and opinion on, the Company’s internal control over financial reporng does not include the internal control over financial reporng of NAPCO Chemical Company, Inc. (“NAPCO”), a wholly-owned subsidiary, whose financial statements reflect total assets and revenues constung less than 4% and less than 1%, respecvely, of the related consolidated financial statement amounts as of and for the year ended April 3, 2022. As indicated in Management’s Report, NAPCO was acquired during fiscal 2022. Management’s asseron on the effecveness of the Company’s internal control over financial reporng excluded internal control over financial reporng of NAPCO. Definion and limitaons of internal control over financial reporng A company’s internal control over financial reporng is a process designed to provide reasonable assurance regarding the reliability of financial reporng and the preparaon of financial statements for external purposes in accordance with generally accepted accounng principles. A company’s internal control over financial reporng includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transacons and disposions of the assets of the company; (2) provide reasonable assurance that transacons are recorded as necessary to permit preparaon of financial statements in accordance with generally accepted accounng principles, and that receipts and expenditures of the company are being made only in accordance with authorizaons of management and directors of the company; and (3) provide reasonable assurance regarding prevenon or mely detecon of unauthorized acquision, use, or disposion of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitaons, internal control over financial reporng may not prevent or detect misstatements. Also, projecons of any evaluaon of effecveness to future periods are subject to the risk that controls may become inadequate because of changes in condions, or that the degree of compliance with the policies or procedures may deteriorate. /s/ GRANT THORNTON LLP Minneapolis, Minnesota May 18, 2022 23 Board of Directors and Shareholders Hawkins, Inc. Report of Independent Registered Public Accounng Firm Opinion on the financial statements We have audited the accompanying consolidated balance sheets of Hawkins, Inc. (a Minnesota corporaon) and subsidiaries (the “Company”) as of April 3, 2022 and March 28, 2021 and the related consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows for the years then ended, and the related notes and financial statement schedule included under Item 15(a) (collecvely referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial posion of the Company as of April 3, 2022 and March 28, 2021, and the results of its operaons and its cash flows for the years then ended, in conformity with accounng principles generally accepted in the United States of America. We also have audited, in accordance with the standards of the Public Company Accounng Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporng as of April 3, 2022 based on criteria established in the 2013 Internal Control—Integrated Framework issued by the Commiee of Sponsoring Organizaons of the Treadway Commission (“COSO”), and our report dated May 18, 2022 expressed an unqualified opinion. Basis for opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounng firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securies laws and the applicable rules and regulaons of the Securies and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluang the accounng principles used and significant esmates made by management, as well as evaluang the overall presentaon of the financial statements. We believe that our audits provide a reasonable basis for our opinion. Crical audit maers Crical audit maers are maers arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit commiee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjecve, or complex judgments. We determined that there are no crical audit maers. /s/ GRANT THORNTON LLP We have served as the Company’s auditor since 2021. Minneapolis, Minnesota May 18, 2022 24 Board of Directors and Shareholders Hawkins, Inc. Report of Independent Registered Public Accounng Firm Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated statements of income, comprehensive income, shareholders’ equity, and cash flows of Hawkins, Inc. and subsidiaries (the Company) for the year ended March 29, 2020 and the related notes and financial statement schedule II (collecvely, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the results of operaons of the Company and its cash flows for the year ended March 29, 2020, in conformity with U.S. generally accepted accounng principles. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounng firm registered with the Public Company Accounng Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securies laws and the applicable rules and regulaons of the Securies and Exchange Commission and the PCAOB. We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluang the accounng principles used and significant esmates made by management, as well as evaluang the overall presentaon of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion. /s/ KPMG LLP We served as the Company’s auditor from 2009 to 2020. Minneapolis, Minnesota May 20, 2020, except as to the stock split and par value adjustments as described in Note 1, which are as of June 2, 2021 25 HAWKINS, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per-share data) ASSETS CURRENT ASSETS: Cash and cash equivalents Trade accounts receivables, net Inventories Prepaid expenses and other current assets Total current assets PROPERTY, PLANT, AND EQUIPMENT: Land Buildings and improvements Machinery and equipment Transportaon equipment Office furniture and equipment Less accumulated depreciaon Net property, plant, and equipment OTHER ASSETS: Right-of-use assets Goodwill Intangible assets, net Deferred compensaon plan asset Other Total other assets Total assets LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES: Accounts payable — trade Accrued payroll and employee benefits Current poron of long-term debt Short-term lease liability Container deposits Other current liabilies Total current liabilies LONG-TERM DEBT, LESS CURRENT PORTION LONG-TERM LEASE LIABILITY PENSION WITHDRAWAL LIABILITY DEFERRED INCOME TAXES DEFERRED COMPENSATION LIABILITY OTHER LONG-TERM LIABILITIES Total liabilies COMMITMENTS AND CONTINGENCIES (Note 13) SHAREHOLDERS’ EQUITY: Common shares; authorized: 60,000,000 shares of $0.01 par value; 20,889,777 and 20,969,746 shares issued and outstanding for 2022 and 2021, respecvely Addional paid-in capital Retained earnings Accumulated other comprehensive income Total shareholders’ equity Total liabilies and shareholders’ equity April 3, 2022 March 28, 2021 $ 3,496 $ 122,826 94,985 6,431 227,738 16,640 118,369 114,763 43,968 10,315 304,055 142,209 161,846 10,606 77,401 80,193 6,783 2,761 177,744 567,328 $ 66,693 $ 19,034 9,913 1,657 1,558 2,611 101,466 115,644 9,143 4,276 23,422 8,402 2,374 264,727 209 46,717 254,384 1,291 302,601 567,328 $ $ $ $ 2,998 90,603 63,864 5,542 163,007 15,235 120,410 109,353 37,646 17,760 300,404 155,792 144,612 11,630 70,720 76,368 5,726 487 164,931 472,550 37,313 18,048 9,907 1,587 1,452 2,155 70,462 88,845 10,231 4,631 24,445 7,322 1,368 207,304 210 51,138 213,898 — 265,246 472,550 See accompanying notes to consolidated financial statements. 26 HAWKINS, INC. CONSOLIDATED STATEMENTS OF INCOME (In thousands, except share and per-share data) Sales Cost of sales Gross profit Selling, general and administrave expenses Operang income Interest expense, net Other income (expense) Income before income taxes Income tax expense Net income Weighted average number of shares outstanding-basic Weighted average number of shares outstanding-diluted Basic earnings per share Diluted earnings per share Cash dividends declared per common share April 03, 2022 Fiscal Year Ended March 28, 2021 March 29, 2020 774,541 $ (628,021) 146,520 (75,326) 71,194 (1,404) 189 69,979 (18,437) 51,542 $ 596,871 $ (473,109) 123,762 (67,884) 55,878 (1,467) 1,440 55,851 (14,871) 40,980 $ 540,198 (439,281) 100,917 (59,246) 41,671 (2,511) (204) 38,956 (10,589) 28,367 20,947,234 21,135,258 21,024,344 21,260,296 21,159,978 21,308,800 2.46 $ 2.44 $ 1.95 $ 1.93 $ 1.34 1.33 0.52250 $ 0.47125 $ 0.46125 $ $ $ $ $ See accompanying notes to consolidated financial statements. 27 HAWKINS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (In thousands) Net income Other comprehensive income, net of tax: Unrealized gain (loss) on interest rate swap Total other comprehensive income (loss) Total comprehensive income April 3, 2022 Fiscal Year Ended March 28, 2021 March 29, 2020 $ $ 51,542 $ 40,980 $ 1,291 1,291 52,833 $ 79 79 41,059 $ 28,367 (396) (396) 27,971 See accompanying notes to consolidated financial statements. 28 HAWKINS, INC. CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (In thousands, except share data) BALANCE — March 31, 2019 Cash dividends declared Share-based compensaon expense Vesng of restricted stock Shares surrendered for payroll taxes ESPP shares issued Shares repurchased Other comprehensive loss, net of tax Net Income BALANCE — March 29, 2020 Cash dividends declared and paid Share-based compensaon expense Vesng of restricted stock Shares surrendered for payroll taxes ESPP shares issued Shares repurchased Other comprehensive loss, net of tax Net income BALANCE — March 28, 2021 Cash dividends declared and paid Share-based compensaon expense Vesng of restricted stock Shares surrendered for payroll taxes ESPP shares issued Shares repurchased Other comprehensive income, net of tax Net income BALANCE — April 3, 2022 Common Shares Shares 21,184,900 $ Amount — — 71,944 (18,320) 77,100 (291,166) — — 21,024,458 $ — — 26,542 (3,314) 88,148 (166,088) — — 20,969,746 $ — — 134,230 (45,390) 71,692 (240,501) — — 20,889,777 $ Addional Paid-in Capital Retained Earnings Accumulated Other Comprehensive Income (Loss) Total Shareholders’ Equity 212 $ — — — — 1 (2) — — 211 $ — — — — 1 (2) — — 210 $ — — 1 — — (2) 52,927 $ 164,405 $ — 2,273 — (343) 1,399 (5,851) — — 50,405 $ — 3,343 — (54) 1,582 (4,138) — — 51,138 $ — 3,818 (1) (1,467) 1,772 (8,543) (9,825) — — — — — — 28,367 182,947 $ (10,029) — — — — — — 40,980 213,898 $ (11,056) — — — — — 317 $ — — — — — — (396) — (79) $ — — — — — — 79 — — $ — — — — — — — — 209 $ — — 46,717 $ — 51,542 254,384 $ 1,291 — 1,291 $ 217,861 (9,825) 2,273 — (343) 1,400 (5,853) (396) 28,367 233,484 (10,029) 3,343 — (54) 1,583 (4,140) 79 40,980 265,246 (11,056) 3,818 — (1,467) 1,772 (8,545) 1,291 51,542 302,601 See accompanying notes to consolidated financial statements. 29 HAWKINS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) CASH FLOWS FROM OPERATING ACTIVITIES: Net income Reconciliaon to cash flows provided by operang acvies: Depreciaon and amorzaon Operang leases (Gain) loss on deferred compensaon assets Deferred income taxes Stock compensaon expense Other Changes in operang accounts (using) providing cash, net of acquisions: Trade receivables Inventories Accounts payable Accrued liabilies Lease liabilies Income taxes Other Net cash provided by operang acvies CASH FLOWS FROM INVESTING ACTIVITIES: Addions to property, plant, and equipment Acquisions Other CASH FLOWS FROM FINANCING ACTIVITIES: Net cash used in invesng acvies Cash dividends paid New shares issued Shares surrendered for payroll taxes Shares repurchased Payments for debt issuance costs Payments on senior secured revolving loan Borrowings on senior secured revolving loan Net cash provided by (used in) financing acvies NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS - beginning of year CASH AND CASH EQUIVALENTS - end of year SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION- Cash paid during the year for income taxes Cash paid for interest Noncash invesng acvies - Capital expenditures in accounts payable $ $ April 3, 2022 Fiscal Year Ended March 28, 2021 March 29, 2020 $ 51,542 $ 40,980 $ 24,129 1,899 (189) (1,501) 3,818 545 (30,526) (30,034) 25,138 2,723 (1,907) 214 (3,014) 42,837 (28,512) (21,546) 302 (49,756) (11,056) 1,772 (1,467) (8,545) (287) (15,000) 42,000 7,417 498 2,998 3,496 $ 19,726 $ 1,197 3,733 22,669 1,896 (1,440) (689) 3,343 203 (21,323) (7,960) 2,551 7,554 (1,837) (235) (1,919) 43,793 (20,794) (51,000) 362 (71,432) (10,029) 1,583 (54) (4,140) — (37,000) 76,000 26,360 (1,279) 4,277 2,998 $ 15,783 $ 1,288 626 28,367 21,584 2,033 233 (1,421) 2,273 656 (3,387) 6,045 4,228 663 (2,025) 586 (933) 58,902 (24,549) — 346 (24,203) (9,825) 1,400 (343) (5,853) — (44,000) 19,000 (39,621) (4,922) 9,199 4,277 11,415 2,413 1,041 See accompanying notes to consolidated financial statements. 30 Note 1 — Nature of Business and Significant Accounng Policies HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Nature of Business - We have three reportable segments: Industrial, Water Treatment and Health and Nutrion. The Industrial Group specializes in providing industrial chemicals, products and services to industries such as agriculture, chemical processing, electronics, energy, food, pharmaceucal and plang. This group also manufactures and sells certain food-grade products, including liquid phosphates, lactates and other blended products. The Water Treatment Group specializes in providing chemicals, products, equipment, services and soluons for potable water, municipal and industrial wastewater, industrial process water and non-residenal swimming pool water. This group has the resources and flexibility to treat systems ranging in size from a single small well to a mul-million-gallon-per-day facility. Our Health and Nutrion Group specializes in providing ingredient distribuon, processing and formulaon soluons to manufacturers of nutraceucal, funconal food and beverage, personal care, dietary supplement and other nutrional food, health and wellness products. This group offers a diverse product porolio including minerals, botanicals and herbs, vitamins and amino acids, excipients, joint products, sweeteners and enzymes. Fiscal Year - Our fiscal year is a 52 or 53-week year ending on the Sunday closest to March 31. Our fiscal 2022 was 53 weeks and our fiscal 2021 fiscal 2020 were both 52 weeks. Fiscal 2023 will be 52 weeks. Principles of Consolidaon - The consolidated financial statements include the accounts of Hawkins, Inc. and its wholly-owned subsidiaries. All intercompany transacons and accounts have been eliminated. Esmates - The preparaon of financial statements in conformity with U.S. generally accepted accounng principles (“GAAP”) requires management to make esmates and assumpons that affect the reported amounts of assets and liabilies, parcularly receivables, inventories, property, plant and equipment, right-of-use assets, goodwill, intangibles, accrued expenses, short-term and long-term lease liability, income taxes and related accounts and the reported amounts of revenues and expenses during the reporng period. Actual results could differ from those esmates. Revenue Recognion - Revenue is measured as the amount of consideraon we expect to receive in exchange for transferring products. Revenue is recognized when we sasfy our performance obligaons under the contract. We recognize revenue upon transfer of control of the promised products to the customer, with revenue recognized at the point in me the customer obtains control of the products. Net sales include products and shipping charges, net of esmates for product returns and any related sales rebates. We esmate product returns based on historical return rates. Using probability assessments, we esmate sales rebates expected to be paid over the term of the contract. The majority of our contracts have a single performance obligaon and are short term in nature. Sales taxes that are collected from customers and remied to governmental authories are accounted for on a net basis and therefore are excluded from net sales. We offer certain customers cash discounts and volume rebates as sales incenves. The discounts and volume rebates are recorded as a reducon in sales at the me revenue is recognized in an amount esmated based on historical experience and contractual obligaons. Shipping and Handling - All shipping and handling amounts billed to customers are included in revenues. Costs incurred related to the shipping and the handling of products are included in cost of sales. 31 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Fair Value Measurements - The financial assets and liabilies that are re-measured and reported at fair value for each reporng period are an interest rate swap and marketable securies. There are no fair value measurements with respect to nonfinancial assets or liabilies that are recognized or disclosed at fair value in our consolidated financial statements on a recurring basis. Assets and liabilies measured at fair value are classified using the following hierarchy, which is based upon the transparency of inputs to the valuaon as of the measurement date: Level 1: Valuaon is based on quoted prices in acve markets for idencal assets or liabilies. Level 2: Valuaon is based on quoted prices in acve markets for similar assets or liabilies, or quoted prices for idencal or similar assets or liabilies in markets that are not acve, or inputs other than quoted prices that are observable or can be corroborated by observable market data for the asset or liability. Level 3: Valuaon is based upon unobservable inputs for the asset or liability that are supported by lile or no market acvity. These fair values are determined using pricing models for which the assumpons ulize management’s esmates or market parcipant assumpons. In making fair value measurements, observable market data must be used when available. When inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement. Cash Equivalents - Cash equivalents include all liquid debt instruments (primarily cash funds and money market accounts) purchased with an original maturity of three months or less. The cash balances, maintained at large commercial banking instuons with strong credit rangs, may, at mes, exceed federally insured limits. Trade Receivables and Concentraons of Credit Risk - Financial instruments, which potenally subject us to a concentraon of credit risk, principally consist of trade receivables. We sell our principal products to a large number of customers in many different industries. As of April 3, 2022, we had a significant concentraon of credit risk, with a single customer represenng approximately 13% of our total trade receivables. There are no other concentraons of credit risk with other single customers from a parcular service or geographic area that would significantly impact us in the near term. To reduce credit risk, we rounely assess the financial strength of our customers. Receivables are reported net of an allowance for credit losses as determined by management at the end of each reporng period. Our receivable allowance in based on an esmate of expected credit losses, with the esmate based on a number of qualitave and quantave factors that, based on collecon experience, may have an impact on repayment risk and ability to collect. Inventories - Inventories, consisng primarily of finished goods, are primarily valued at the lower of cost or net realizable value, with cost for approximately 73% of our inventory determined using the last-in, first-out (“LIFO”) method. Cost for the other 27% of our total inventory is determined using the first-in, first-out (“FIFO”) method. Leases - We determine if an arrangement is a lease at incepon. Right-of-use ("ROU") assets include operang leases. Lease liabilies for operang leases are classified in "short-term lease liabilies" and "long-term lease liabilies" in our consolidated balance sheet. ROU assets and related liabilies are recognized at commencement date based on the present value of the lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the informaon available at commencement date in determining the present value of lease payments. Lease terms may include opons to extend or terminate the lease when it is reasonably certain that we will exercise that opon. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease and non-lease components are generally accounted for separately for real estate leases. For non-real estate leases, we account for the lease and non- lease components as a single lease component. 32 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Property, Plant and Equipment - Property is stated at cost and depreciated or amorzed over the lives of the assets, using the straight-line method. Esmated lives are: 10 to 40 years for buildings and improvements; 3 to 20 years for machinery and equipment; and 3 to 10 years for transportaon equipment and office furniture and equipment including computer systems. Leasehold improvements are amorzed over the lesser of their esmated useful lives or the remaining lease term. Depreciaon and amorzaon expense is recorded in our Consolidated Statement of Income within cost of goods sold and selling, general and administrave expense, depending on the use of the underlying asset. We recorded depreciaon expense of $17.7 million for fiscal 2022, $16.8 million for fiscal 2021 and $16.5 million for fiscal 2020. Significant improvements that add to producve capacity or extend the lives of properes are capitalized. Costs for repairs and maintenance are charged to expense as incurred. When property is rered or otherwise disposed of, the cost and related accumulated depreciaon or amorzaon are removed from the accounts and any related gains or losses are included in income. We review the recoverability of long-lived assets to be held and used, such as property, plant and equipment, when events or changes in circumstances occur that indicate the carrying value of the asset group may not be recoverable, such as prolonged industry downturn or significant reducons in projected future cash flows. The assessment of possible impairment is based on our ability to recover the carrying value of the asset group from the expected future pre-tax cash flows (undiscounted) of the related asset group. If these cash flows are less than the carrying value of such asset group, an impairment loss would be measured by the amount the carrying value exceeds the fair value of the long-lived asset group. The measurement of impairment requires us to esmate future cash flows and the fair value of long-lived assets. We did not incur any asset write-off charge in fiscal 2022 related to the impairment of long-lived assets. Asset write-off charges were $0.2 million during fiscal 2021 and $0.6 million during fiscal 2020. Goodwill and Idenfiable Intangible Assets - Goodwill represents the excess of the cost of acquired businesses over the fair value of idenfiable tangible net assets and idenfiable intangible assets purchased. Goodwill is tested at least annually for impairment, and is tested for impairment more frequently if events or changes in circumstances indicate that the asset might be impaired. Our annual test for impairment is as of the first day of our fourth fiscal quarter. As of December 27, 2021, we performed an analysis of qualitave factors for our Industrial, Water Treatment and Health and Nutrion reporng units to determine whether it is more likely than not that the fair value of either of these reporng units was less than its carrying amount as a basis for determining whether it is necessary to perform a quantave goodwill impairment test. Based on management’s analysis of qualitave factors, we determined that it was not necessary to perform a quantave goodwill impairment test for any of these reporng units. Goodwill impairment assessments were also completed in the fourth quarters of fiscal 2021 and 2020 and similarly, we did not record a goodwill impairment charge. Our primary idenfiable intangible assets include customer lists, trade secrets, non-compeon agreements, trademarks and trade names acquired in previous business acquisions. Idenfiable intangible assets with finite lives are amorzed whereas idenfiable intangible assets with indefinite lives are not amorzed. The values assigned to the intangible assets with finite lives are being amorzed on average over a remaining useful life of approximately 12 years. Idenfiable intangible assets that are subject to amorzaon are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. No such events or changes in circumstances occurred during fiscal 2022, 2021 or 2020. Idenfiable intangible assets not subject to amorzaon are tested for impairment annually or more frequently if events warrant. The impairment test consists of a qualitave assessment to determine whether it is more likely than not that the asset is impaired. Based on management’s analysis of qualitave factors, we determined that it was not necessary to perform an annual quantave impairment test for fiscal 2022, 2021 or 2020. 33 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Income Taxes - We account for income taxes under the asset and liability method, which requires the recognion of deferred tax assets and liabilies for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilies are determined on the basis of the differences between the financial statements and tax basis of assets and liabilies using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilies is recognized in income tax expense in the period that includes the enactment date. The deferred tax assets and liabilies are analyzed regularly, and management assesses the likelihood that deferred tax assets will be recovered from future taxable income. We record any interest and penales related to income taxes as income tax expense in the consolidated statements of income. We recognize the effect of income tax posions only if those posions are more-likely-than-not to be sustained. Recognized income tax posions are measured at the largest amount of tax with a greater than 50 percent likelihood of being realized upon ulmate selement with the related tax authority. Changes in recognion or measurement are reflected in the period in which the facts and circumstances change. Stock-Based Compensaon - We account for stock-based compensaon on a fair value basis. The esmated grant date fair value of each stock-based award is recognized in expense over the requisite service period (generally the vesng period). Non-vested share awards are recorded as expense over the requisite service periods based on the stock price on the date of grant. Earnings Per Share - Basic earnings per share (“EPS”) are computed by dividing net income by the weighted-average number of common shares outstanding. Diluted EPS are computed by dividing net income by the weighted-average number of common shares outstanding including the incremental shares assumed following: to be as performance units calculated using stock. Basic EPS were restricted issued and the and diluted April 03, 2022 March 28, 2021 March 29, 2020 Weighted average common shares outstanding — basic Diluve impact of stock performance units and restricted stock Weighted average common shares outstanding — diluted 20,947,234 188,024 21,135,258 21,024,344 235,952 21,260,296 21,159,978 148,822 21,308,800 There were no shares or stock opons excluded from the calculaon of weighted average common shares for diluted EPS for fiscal 2022, 2021 or 2020. Stock Split - In fiscal 2021, we effected a two-for-one stock split of our common stock and adjusted the par value of our common stock to $.01 par value. Our consolidated financial statements, related notes, and other financial data contained in this report have been adjusted to give retroacve effect to the stock split for all periods presented. Derivave Instruments and Hedging Acvies - We are subject to interest rate risk associated with our variable rate debt. We have in place an interest rate swap agreement which has been designated as a cash flow hedge, the purpose of which is to eliminate the cash flow impact of interest rate changes on a poron of our variable-rate debt. The interest rate swap is measured at fair value on the contract date and is subsequently remeasured to fair value at each reporng date. Changes in the fair value of a derivave that is highly effecve, and that is designated and qualifies as a cash flow hedge, are recorded in other comprehensive income, unl the consolidated statement of income is affected by the variability in cash flows of the designated hedged item. To the extent that the hedge is ineffecve, changes in the fair value are recognized in the Statement of Income. Recently Issued Accounng Pronouncements We do not expect that any recently issued accounng pronouncements will have a material effect on our financial statements. Recently Adopted Accounng Pronouncements In December 2019, the Financial Accounng Standards Board ("FASB") issued Accounng Standards Update ("ASU") 2019-12, Income Taxes (Topic 740) - Simplifying the Accounng for Income Taxes, removing certain excepons for investments, intra-period allocaons and interim calculaons and adding guidance to reduce complexity in accounng for income taxes. We adopted this guidance at the beginning of fiscal 2022. Our adopon of this ASU did not have a material impact on the Company's consolidated financial posion, results of operaons or cash flows. 34 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 2 — Acquisions Acquision of NAPCO Chemical Company, Inc.: On December 30, 2021, we acquired substanally all the assets of NAPCO Chemical Company, Inc. ("NAPCO"), under the terms of an asset purchase agreement with NAPCO and certain other pares thereto, to further the geographic reach of our Water Treatment segment. We paid $18.5 million at closing for the acquision, and an addional $0.5 million for a working capital adjustment. NAPCO manufactures and distributes water treatment chemicals from three locaons in Texas. The results of operaons since the acquision date, and the assets, including the goodwill associated with this acquision, are included in our Water Treatment segment. Costs associated with this transacon were not material and were expensed as incurred. The acquision has been accounted for as a business combinaon, under which the total purchase price is allocated to the net tangible and intangible assets and liabilies of NAPCO acquired in connecon with the acquision based on their esmated fair values. We esmated the fair values of the assets acquired and liabilies assumed using a discounted cash flow analysis (income approach). Of the total $19 million purchase price, we allocated $9.4 million to finite- lived intangible assets, primarily customer relaonships to be amorzed over 18 years, $3.6 million to property, plant and equipment and $1.5 million to net working capital. The residual amount of $4.5 million was allocated to goodwill. The goodwill recognized as a result of this acquision is primarily aributable to strategic and synergisc benefits, as well as the assembled workforce. Such goodwill is expected to be deducble for tax purposes. The purchase price allocaon is final. Acquision of Water and Waste Speciales, Inc.: On October 29, 2021, we acquired substanally all the assets of Water and Waste Speciales, Inc., under the terms of a purchase agreement with Water and Waste Speciales and its shareholders, to further the geographic reach of our Water Treatment segment. We paid $1.4 million at closing for the acquision. Water and Waste Speciales was a water treatment chemical distribuon company operang primarily in Alabama. The results of operaons since the acquision date, and the assets, including the goodwill associated with this acquision, are included in our Water Treatment segment. Costs associated with this transacon were not material and were expensed as incurred. The acquision has been accounted for as a business combinaon, under which the total purchase price is allocated to the net tangible and intangible assets and liabilies of Water and Waste Speciales acquired in connecon with the acquision based on their esmated fair values. We esmated the fair values of the assets acquired and liabilies assumed using a discounted cash flow analysis (income approach). Of the total $1.4 million purchase price, we allocated $0.5 million to finite-lived intangible assets, primarily customer relaonships to be amorzed over 11 years, and $0.4 million to property, plant and equipment. The residual amount of $0.5 million was allocated to goodwill. The goodwill recognized as a result of this acquision is primarily aributable to strategic and synergisc benefits, as well as the assembled workforce. Such goodwill is expected to be deducble for tax purposes. The purchase price allocaon is final. Acquision of Southeast Water Systems LLC: On September 20, 2021, we acquired substanally all the assets of Southeast Water Systems LLC, under the terms of an asset purchase agreement with Southeast Water Systems and its shareholders, to further the geographic reach of our Water Treatment segment. We paid $1.2 million at closing for the acquision and may pay up to an addional $1.0 million over the next three years based on achieving certain goals. Southeast Water Systems supplied and installed water treatment chemical equipment to its customers located primarily in Alabama, southern Georgia and the Florida panhandle. The results of operaons since the acquision date, and the assets, including the goodwill associated with this acquision, are included in our Water Treatment segment. Costs associated with this transacon were not material and were expensed as incurred. The acquision has been accounted for as a business combinaon, under which the total purchase price is allocated to the net tangible and intangible assets and liabilies of Southeast Water Systems acquired in connecon with the acquision based on their esmated fair values. We esmated the fair values of the assets acquired and liabilies assumed using a discounted cash flow analysis (income approach). Of the total $2.2 million purchase price, which includes a conngent consideraon liability of $1.0 million, we allocated $0.4 million to finite-lived intangible assets, primarily customer relaonships to be amorzed over 10 years, and $0.1 million to property, plant and equipment. The residual amount of $1.7 million was allocated to goodwill. The goodwill recognized as a result of this acquision is primarily aributable to strategic and synergisc benefits, as well as the assembled workforce. Such goodwill is expected to be deducble for tax purposes. The purchase price allocaon is final. 35 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Acquision of C&L Aqua Professionals, Inc. and LC Blending, Inc.: In fiscal 2021, we acquired substanally all the assets of C&L Aqua Professionals, Inc. and LC Blending, Inc. (together, "C&L Aqua") under the terms of an asset purchase agreement among us, C&L Aqua and its shareholders, to further the geographic reach of our Water Treatment segment. We paid $16 million for the acquision. C&L Aqua was a water treatment chemical distribuon company operang primarily in Louisiana. The results of operaons since the acquision date, and the assets, including the goodwill associated with this acquision, are included in our Water Treatment segment. Costs associated with this transacon were not material and were expensed as incurred. The acquision has been accounted for as a business combinaon, under which the total purchase price is allocated to the net tangible and intangible assets and liabilies of C&L Aqua acquired in connecon with the acquision based on their esmated fair values. We esmated the fair values of the assets acquired and liabilies assumed using a discounted cash flow analysis (income approach). Of the $16 million purchase price, we preliminarily allocated $8.2 million to finite-lived intangible assets, primarily customer relaonships to be amorzed over 18 years, $3.6 million to property, plant and equipment, and $1.1 million to net working capital. The residual amount of $3.1 million was allocated to goodwill. The goodwill recognized as a result of this acquision is primarily aributable to strategic and synergisc benefits, as well as the assembled workforce. Such goodwill is expected to be deducble for tax purposes. Acquision of Property: In fiscal 2021, we acquired a manufacturing facility on 28 acres located adjacent to our facility in Rosemount, Minnesota to allow further expansion and growth in both our Industrial and Water Treatment segments. We paid $10 million for the property. The purchase of this facility adds approximately 40,000 square feet of manufacturing and warehouse space to bring us to a total of 105,000 square feet of space on 56 acres of land in the area, with rail access at both of the sites to allow for future growth and provide for supply chain flexibility on certain raw materials to beer serve our customers. This acquision has been accounted for as an asset acquision, under which the total purchase price is allocated to the net tangible assets acquired based on their esmated fair values. Of the $10 million purchase price, $4.6 million was allocated to buildings, $3.7 million was allocated to land, $1.4 million was allocated to equipment, and $0.3 million was allocated to site improvements. Acquision of American Development Corporaon of Tennessee, Inc.: In fiscal 2021, we acquired substanally all the assets of American Development Corporaon of Tennessee, Inc. (“ADC”) under the terms of an asset purchase agreement among us, ADC and its shareholders, to further the geographic reach of our Water Treatment segment. We paid $25 million for the acquision. ADC was a water treatment chemical distribuon company operang primarily in Tennessee, Georgia and Kentucky. The results of operaons since the acquision date, and the assets, including the goodwill associated with this acquision, are included in our Water Treatment segment. Costs associated with this transacon were not material and were expensed as incurred. The acquision has been accounted for as a business combinaon, under which the total purchase price is allocated to the net tangible and intangible assets and liabilies of ADC acquired in connecon with the acquision based on their esmated fair values. We esmated the fair values of the assets acquired and liabilies assumed using a discounted cash flow analysis (income approach). Of the $25 million purchase price, we allocated $13.3 million to finite-lived intangible assets, primarily customer relaonships to be amorzed over 17 years, $1.6 million to property, plant and equipment, and $0.9 million to net working capital. The residual amount of $9.2 million was allocated to goodwill. The goodwill recognized as a result of this acquision is primarily aributable to strategic and synergisc benefits, as well as the assembled workforce. Such goodwill is expected to be deducble for tax purposes. 36 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 3 — Revenue Our revenue arrangements generally consist of a single performance obligaon to transfer promised goods or services. We disaggregate revenues from contracts with customers by both operang segments and types of product sold. Reporng by operang segment is pernent to understanding our revenues, as it aligns to how we review the financial performance of our operaons. Types of products sold within each operang segment help us to further evaluate the financial performance of our segments. The following table disaggregates external customer net sales by major revenue stream: (In thousands) Manufactured, blended or repackaged products Distributed specialty products (3) Bulk products Other (2) (1) Total external customer sales (In thousands) Manufactured, blended or repackaged products Distributed specialty products (3) Bulk products Other (2) (1) Total external customer sales (In thousands) Manufactured, blended or repackaged products Distributed specialty products (3) Bulk products Other (2) (1) Total external customer sales Industrial 318,514 — 61,443 6,981 386,938 Industrial 231,427 — 38,378 3,556 273,361 Industrial 222,161 — 49,864 3,199 275,224 $ $ $ $ $ $ Fiscal Year Ended April 3, 2022: Health and Nutrion Water Treatment 205,350 — 20,211 2,572 228,133 $ $ 34,690 124,312 — 468 159,470 Fiscal Year Ended March 28, 2021: Health and Nutrion Water Treatment 152,694 — 16,067 1,243 170,004 $ $ 38,270 115,317 — (81) 153,506 Fiscal Year Ended March 29, 2020: Health and Nutrion Water Treatment 139,917 — 18,481 1,497 159,895 $ $ 14,770 90,065 — 244 105,079 $ $ $ $ $ $ $ $ $ $ $ $ Total 558,554 124,312 81,654 10,021 774,541 Total 422,391 115,317 54,445 4,718 596,871 Total 376,848 90,065 68,345 4,940 540,198 (1) For our Industrial and Water Treatment segments, this line includes our non-bulk specialty products that we either manufacture, blend, repackage, resell in their original form, or direct ship to our customers in smaller quanes, and services we provide for our customers. For our Health and Nutrion segment, this line includes products manufactured, processed or repackaged in our facility and/or with our equipment (2) This line includes non-manufactured distributed specialty products in our Health and Nutrion segment, which may be sold out of one of our facilies or direct shipped to our customers (3) This line includes bulk products in our Industrial and Water Treatment segments that we do not modify in any way, but receive, store, and ship from our facilies, or direct ship to our customers in large quanes. 37 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 4 — Derivave Instruments We have in place an interest rate swap agreement to manage the risk associated with a poron of our variable-rate long-term debt. We do not ulize derivave instruments for speculave purposes. The interest rate swap involves the exchange of fixed-rate and variable-rate payments without the exchange of the underlying noonal amount on which the interest payments are calculated. The noonal amount of the swap agreement is $60 million and it will terminate on May 1, 2027. We have designated this swap as a cash flow hedge and have determined that it qualified for hedge accounng treatment. For so long as the hedge is effecve, changes in fair value of the cash flow hedge are recorded in other comprehensive income or loss (net of tax) unl income or loss from the cash flows of the hedged item is realized. We previously had in place an interest rate swap agreement to manage the risk associated with a poron of our variable-rate long-term debt. The $20 million swap agreement terminated on December 23, 2020. We had designated this swap as a cash flow hedge and determined that it qualified for hedge accounng treatment. For so long as the hedge was effecve, changes in fair value of the cash flow hedge were recorded in other comprehensive income or loss (net of tax) unl income or loss from the cash flows of the hedged item was realized. For the years ended April 3, 2022 and March 28, 2021, we recorded $1.3 million and $0.1 million in other comprehensive income related to unrealized gains (net of tax) on the cash flow hedge. For the year ended March 29, 2020, we recorded $0.4 million in other comprehensive income related to unrealized losses (net of tax) on the cash flow hedge described above. Included in other other long-term assets on our consolidated balance sheet was $1.8 million as of April 3, 2022. Included in other current liabilies on our consolidated balance sheet was $0.1 million as of March 29, 2020. By their nature, derivave instruments are subject to market risk. Derivave instruments are also subject to credit risk associated with counterpares to the derivave contracts. Credit risk associated with derivaves is measured based on the replacement cost should the counterparty with a contract in a gain posion to us fail to perform under the terms of the contract. While the current interest rate swap is in effect, we do not ancipate nonperformance by the counterparty. Note 5 – Fair Value Measurements Our financial assets and liabilies are measured at fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transacon between market parcipants at the measurement date (exit price). The carrying value of cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these instruments. Because of the variable-rate nature of our debt under our credit facility, our debt also approximates fair value. Assets and Liabilies Measured at Fair Value on a Recurring Basis. The fair value hierarchy requires the use of observable market data when available. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its enrety. Our assessment of the significance of a parcular item to the fair value measurement in its enrety requires judgment, including the consideraon of inputs specific to the asset or liability. Our financial assets that are measured at fair value on a recurring basis are an interest rate swap and assets held in a deferred compensaon rerement plan. Both of these assets are classified as other long-term assets on our balance sheet, with the poron of the deferred compensaon rerement plan assets expected to be paid within twelve months classified as current assets. The fair value of the interest rate swap is determined by the respecve counterpares based on interest rate changes. Interest rate swaps are valued based on observable interest rate yield curves for similar instruments. The deferred compensaon plan assets relate to contribuons made to a non-qualified compensaon plan on behalf of certain employees who are classified as “highly compensated employees” as determined by IRS guidelines. The assets are part of a rabbi trust and the funds are held in mutual funds. The fair value of the deferred compensaon is based on the quoted market prices for the mutual funds at the end of the period. The following table summarizes the balances of assets measured at fair value on a recurring basis as of April 3, 2022 and March 28, 2021. (In thousands) Assets Deferred compensaon plan assets Interest rate swap 0 April 3, 2022 March 28, 2021 Level 1 Level 2 $ 7,038 1,769 $ 5,946 — 38 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 6 – Assets Held for Sale We have no assets classified as held for sale as of April 3, 2022. Included in assets held for sale as of March 28, 2021 was $0.7 million for an office building in St. Louis, Missouri that was ulized in the administraon of our Industrial segment, and $0.2 million for a water treatment branch located in Eldridge, Iowa, which has been relocated to another owned facility. Both were sold in the first quarter of fiscal 2022. These amounts were recorded as assets held for sale within prepaid expenses and other current assets on our balance sheet. Note 7 — Inventories Inventories at April 3, 2022 and March 28, 2021 consisted of the following: (In thousands) Inventory (FIFO basis) LIFO reserve Net inventory 2022 2021 $ $ 116,325 $ (21,340) 94,985 $ 69,438 (5,574) 63,864 The FIFO value of inventories accounted for under the LIFO method was $83.7 million at April 3, 2022 and $46.8 million at March 28, 2021. The remainder of the inventory was valued and accounted for under the FIFO method. 39 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 8 — Goodwill and Other Idenfiable Intangible Assets The carrying amount of goodwill for each of our three reportable segments were as follows: (In thousands) Balance as of March 29, 2020 $ Addion due to acquisions Balance as of March 28, 2021 Addion due to acquisions Balance as of April 3, 2022 $ $ Industrial Water Treatment Health and Nutrion Total 6,495 $ — 6,495 $ — 6,495 $ 7,000 $ 12,280 19,280 $ 6,681 25,961 $ 44,945 $ — 44,945 $ — 44,945 $ 58,440 12,280 70,720 6,681 77,401 The following is a summary of our idenfiable intangible assets as of April 3, 2022 and March 28, 2021: (In thousands) Finite-life intangible assets: Customer relaonships Trademarks and trade names Other finite-life intangible assets Total finite-life intangible assets Indefinite-life intangible assets Total intangible assets, net (In thousands) Finite-life intangible assets: Customer relaonships Trademarks and trade names Other finite-life intangible assets Total finite-life intangible assets Indefinite-life intangible assets Total intangible assets, net Gross Amount 2022 Accumulated Amorzaon Net carrying value 109,644 $ 6,370 3,904 119,918 1,227 121,145 $ (32,399) $ (4,746) (3,807) (40,952) — (40,952) $ 77,245 1,624 97 78,966 1,227 80,193 Gross Amount 2021 Accumulated Amorzaon Net carrying value 99,588 $ 6,210 3,833 109,631 1,227 110,858 $ (26,522) $ (4,275) (3,693) (34,490) — (34,490) $ 73,066 1,935 140 75,141 1,227 76,368 $ $ $ $ Intangible asset amorzaon expense was $6.5 million during fiscal 2022, $5.8 million during fiscal 2021, and $5.1 million during fiscal 2020. The esmated future amorzaon expense for idenfiable intangible assets is as follows: (In thousands) Fiscal 2023 Fiscal 2024 Fiscal 2025 Fiscal 2026 Fiscal 2027 Thereaer Total Intangible Assets 6,923 $ 6,707 6,707 6,606 6,305 45,718 78,966 $ 40 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 9 – Debt On March 31, 2022, we entered into a second amended and restated credit agreement (the “Credit Agreement”) with U.S. Bank Naonal Associaon (“U.S. Bank”) as Sole Lead Arranger and Sole Book Runner, and other lenders from me to me party thereto (collecvely, the “Lenders”), whereby U.S. Bank is also serving as Administrave Agent. The Credit Agreement refinanced the revolving loan under our previous credit agreement with U.S. Bank and provides us with senior secured revolving credit facilies (the “Revolving Loan Facility”) totaling $250.0 million. The Revolving Loan Facility includes a $15 million leer of credit subfacility and $25 million swingline subfacility. The Revolving Loan Facility has a five-year maturity date, maturing on April 30, 2027. The Revolving Loan Facility is secured by substanally all of our personal property assets and those of our subsidiaries. We used $126.0 million of the proceeds from the Revolving Loan Facility to refinance the obligaons under the previous credit facility. We may use the remaining amount of the Revolving Loan Facility for working capital, capital expenditures, share repurchases, restricted payments and acquisions permied under the Credit Agreement, and other general corporate purposes. At April 3, 2022, the effecve interest rate on our borrowings was 1.2%. In addion to paying interest on the outstanding principal under the Revolving Loan Facility, we are required to pay a commitment fee on the unulized commitments thereunder. The commitment fee is between 0.15% and 0.25%, depending on our leverage rao. Debt issuance costs of $0.3 million paid to the lenders in connecon with the Credit Agreement, as well as unamorzed debt issuance costs of $0.1 million paid in connecon with the previous credit facility, are reflected as a reducon of debt and are being amorzed as interest expense over the term of the Revolving Loan Facility. The Credit Agreement requires us to maintain (a) a minimum fixed charge coverage rao of 1.15 to 1.00 and (b) a maximum total cash flow leverage rao of 3.0 to 1.0. The Credit Agreement also contains other customary affirmave and negave covenants, including covenants that restrict our ability to incur addional indebtedness, dispose of significant assets, make certain investments, including any acquisions other than permied acquisions, make certain payments, enter into sale and leaseback transacons, grant liens on our assets or enter into rate management transacons, subject to certain limitaons. We are permied to make distribuons, pay dividends and repurchase shares so long as no default or event of default exists or would exist as a result thereof. We are permied to make distribuons, pay dividends and repurchase shares so long as no default or event of default exists or would exist as a result thereof. As of April 3, 2022, we were in compliance with all required covenants. Debt at April 3, 2022 and March 28, 2021 consisted of the following: (In thousands) Senior secured revolving loan Less: unamorzed debt issuance costs Total debt, net of debt issuance costs Less: current poron of long-term debt, net of current unamorzed debt issuance costs Total long-term debt April 3, 2022 March 28, 2021 $ $ 126,000 $ (443) 125,557 (9,913) 115,644 $ 99,000 (248) 98,752 (9,907) 88,845 41 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 10 — Share-Based Compensaon Performance-Based Restricted Stock Units. Our Board of Directors has approved a performance-based equity compensaon arrangement for our execuve officers. This performance-based arrangement provides for the grant of performance-based restricted stock units that represent a possible future issuance of restricted shares of our common shares based on our pre-tax income target for the applicable fiscal year. The actual number of restricted shares to be issued to each execuve officer will be determined when our final financial informaon becomes available aer the applicable fiscal year and will be between zero shares and 88,524 shares in the aggregate for fiscal 2022. The restricted shares issued, if any, will fully vest two years aer the end of the fiscal year on which the performance is based. We record the compensaon expense for the outstanding performance share units and then-converted restricted stock over the life of the awards. The following table represents the restricted stock acvity for fiscal 2021 and 2022: Outstanding at beginning of fiscal 2020 Granted Vested Forfeited Outstanding at end of fiscal 2020 Granted Vested Forfeited Outstanding at end of fiscal 2021 Granted Vested Forfeited Outstanding at end of fiscal 2022 Shares 65,766 $ 138,504 (55,240) — 149,030 $ 129,626 (10,526) (29,010) 239,120 $ 111,618 (123,002) (13,258) 214,478 $ Weighted- Average Grant Date Fair Value 21.83 17.25 23.01 — 17.13 18.69 15.68 17.92 17.94 31.74 17.25 18.69 25.48 The weighted average grant date fair value of performance-based restricted shares issued in fiscal 2022 was $31.74, fiscal 2021 was $18.69 and fiscal 2020 was $17.25. We recorded compensaon expense on performance-based restricted stock of approximately $2.9 million for fiscal 2022, $2.5 million for fiscal 2021 and $1.5 million for fiscal 2020, substanally all of which was recorded in selling, general and administrave (“SG&A”) expense in the Consolidated Statements of Income. The total fair value of performance-based restricted stock units vested was $2.1 million in fiscal 2022, $0.2 million in fiscal 2021 and $1.3 million in fiscal 2020. Unl the performance-based restricted stock units result in the issuance of restricted stock, the amount of expense recorded each period is dependent upon our esmate of the number of shares that will ulmately be issued and our then current common share price. Upon issuance of restricted stock, we record compensaon expense over the remaining vesng period using the award date closing price. Unrecognized compensaon expense related to non-vested restricted stock and non-vested restricted share units as of April 3, 2022 was $3.9 million and is expected to be recognized over a weighted average period of 1.2 years. 42 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Restricted Stock Awards. As part of their retainer, our non-employee directors receive restricted stock for their Board services. The restricted stock awards are expensed over a one-year vesng period, based on the market value on the date of grant. The following table represents the Board’s restricted stock acvity for fiscal 2021 and 2022: Outstanding at beginning of fiscal 2020 Granted Vested Forfeited Outstanding at end of fiscal 2020 Granted Vested Forfeited Outstanding at end of fiscal 2021 Granted Vested Forfeited Outstanding at end of fiscal 2022 Shares Weighted- Average Grant Date Fair Value 16,704 $ 16,016 (16,704) — 16,016 $ 13,186 (16,016) (1,958) 11,228 $ 10,287 (11,228) — 10,287 $ 17.95 21.84 17.95 — 21.84 25.59 21.84 25.53 25.60 32.80 25.60 — 32.80 Annual expense related to the value of restricted stock was $0.3 million in fiscal 2022, 2021 and 2020, and was recorded in SG&A expense in the Consolidated Statements of Income. Unrecognized compensaon expense related to non-vested restricted stock awards as of April 3, 2022 was $0.1 million and is expected to be recognized over a weighted average period of 0.3 years. Note 11 — Share Repurchases Our board of directors has authorized the repurchase of up to 1,600,000 shares of our outstanding common shares. The shares may be repurchased on the open market or in privately negoated transacons subject to applicable securies laws and regulaons. Upon repurchase of the shares, we reduce our common shares for the par value of the shares with the excess applied against addional paid-in capital. We repurchased 240,501 common shares at an aggregate purchase price of $8.5 million during fiscal 2022. We repurchased 166,088 common shares at an aggregate purchase price of $4.1 million during fiscal 2021. We repurchased 291,166 common shares at an aggregate purchase price of $5.9 million during fiscal 2020. As of April 3, 2022, the number of shares available to be purchased under the share repurchase program was 311,005. Note 12 — Profit Sharing, Employee Stock Ownership, Employee Stock Purchase and Pension Plans Company Sponsored Plans. The majority of our non-bargaining unit employees are eligible to parcipate in a company-sponsored profit sharing plan. Contribuons are made at our discreon subject to a maximum amount allowed under the Internal Revenue Code (“IRC”). The profit sharing plan contribuon level for each employee depends upon date of hire, and was 2.5% or 5.0% of each employee’s eligible compensaon for fiscal 2022, 2021 and 2020. We also have in place a rerement plan covering our collecve bargaining unit employees. The rerement plan provides for a contribuon of 2.5% or 5.0% of each employee’s eligible annual wages depending on their hire date. In addion to the employer contribuons described above, both the profit sharing plan and the rerement plan include a 401(k) plan that allows employees to contribute pre-tax earnings up to the maximum amount allowed under the IRC, with an employer match of up to 5% of the employee’s eligible compensaon. We have two employee stock ownership plans (“ESOPs”), one covering the majority of our non-bargaining unit employees and the other covering our collecve bargaining unit employees. Contribuons to the plan covering our non-bargaining unit employees are made at our discreon. Contribuons to both plans are subject to a maximum amount allowed under the IRC, and were 2.5% or 5.0% of each employee’s eligible wages, depending on each eligible employee’s hire date, for fiscal 2022, 2021 and 2020. 43 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) We have a nonqualified deferred compensaon plan covering employees who are classified as “highly compensated employees” as determined by IRS guidelines for the plan year and who were hired on or before April 1, 2012. Employees who are eligible for the nonqualified deferred compensaon plan for any plan year are not eligible for the profit sharing plan contribuon or the ESOP contribuons described above for that plan year. Our contribuon to the nonqualified deferred compensaon plan for fiscal 2022, 2021 and 2020 was 10% of each employee’s eligible compensaon, subject to the maximum amount allowed under the IRC. We have an employee stock purchase plan (“ESPP”) covering substanally all of our employees. The ESPP allows employees to purchase newly-issued shares of the Company’s common shares at a discount from market. The number of new shares issued under the ESPP was 71,692 in fiscal 2022, 88,148 in fiscal 2021 and 77,100 in fiscal 2020. contribuon the following represents The (In thousands) Non-bargaining unit employee plans: Profit sharing 401(k) matching contribuons ESOP Nonqualified deferred compensaon plan Bargaining unit employee plans ESPP - all employees Total contribuon expense expense for these company-sponsored plans 2022 for fiscal 2021 2022, 2021 and 2020: 2020 $ $ 1,056 $ 3,122 1,056 1,355 589 549 7,727 $ 994 2,650 994 1,327 555 556 7,076 $ $ 631 2,399 631 1,262 481 431 5,835 In 2013, we withdrew from a collecvely bargained mulemployer pension plan and recorded a liability for our share of the unfunded vested benefits. Payments of approximately $0.5 million per year are being made through 2034. Note 13 — Commitments and Conngencies Ligaon. As of April 3, 2022, there were no material pending legal proceedings, other than ordinary roune ligaon incidental to the business, to which we or any of our subsidiaries are a party or of which any of our property is the subject. Legal fees associated with such maers are expensed as incurred. Asset Rerement Obligaons. We have three leases of land which contain terms that state that at the end of the lease term, we have a specified amount of me to remove the property and buildings. Including available lease extensions, these leases expire in 2023, 2033 and 2044. At that me, anything that remains on the land becomes the property of the lessor, and the lessor has the opon to either maintain the property or remove the property at our expense. We have not been able to reasonably esmate the fair value of the asset rerement obligaons, primarily due to the combinaon of the following factors: certain of the leases do not expire in the near future; we have a history of extending the leases with the lessors and currently intend to do so at expiraon of the lease periods; the lessors do not have a history of terminang leases with their tenants; and because it is more likely than not that the buildings will have value at the end of the lease life and therefore, may not be removed by either the lessee or the lessor. Therefore, in accordance with accounng guidance related to asset rerement and environmental obligaons, we have not recorded an asset rerement obligaon as of April 3, 2022. We will connue to monitor the factors surrounding the requirement to record an asset rerement obligaon and will recognize the fair value of a liability in the period in which it is incurred and a reasonable esmate can be made. 44 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 14 — Income Taxes The provisions for income taxes for fiscal 2022, 2021 and 2020 were as follows: (In thousands) Federal — current State — current Total current Federal — deferred State — deferred Total deferred Total provision 2022 2021 2020 $ $ 14,736 $ 5,202 19,938 (1,054) (447) (1,501) 18,437 $ 11,169 $ 4,391 15,560 (302) (387) (689) 14,871 $ 8,447 3,563 12,010 (976) (445) (1,421) 10,589 Reconciliaons of the provisions for income taxes to the applicable federal statutory income tax rate for fiscal 2022, 2021 and 2020 are listed below. 2022 2021 2020 Statutory federal income tax State income taxes, net of federal deducon ESOP dividend deducon on allocated shares Other — net Total 21.0 % 5.6 % (0.2)% (0.1)% 26.3 % 21.0 % 5.9 % (0.2)% (0.1)% 26.6 % The tax effects of items comprising our net deferred tax liability as of April 3, 2022 and March 28, 2021 are as follows: (In thousands) Deferred tax assets: 2022 2021 Trade receivables Stock compensaon accruals Pension withdrawal liability Lease liability Other Total deferred tax assets Deferred tax liabilies: Inventories Prepaid expenses Excess of tax over book depreciaon Intangible assets ROU asset Unrealized gain on interest rate swap Total deferred tax liabilies Net deferred tax liabilies $ $ $ $ $ 99 $ 1,823 1,250 2,916 3,097 9,185 $ (1,288) $ (937) (12,234) (14,806) (2,864) (478) (32,607) $ (23,422) $ 21.0 % 5.7 % (0.3)% 0.8 % 27.2 % 134 1,341 1,344 3,191 2,882 8,892 (2,815) (864) (11,249) (15,269) (3,140) — (33,337) (24,445) As of April 3, 2022, the Company has determined that it is more likely than not that the deferred tax assets at April 3, 2022 will be realized either through future taxable income or reversals of taxable temporary differences. We are subject to U.S. federal income tax as well as income tax of mulple state jurisdicons. The tax years prior to our fiscal year ended March 31, 2019 are closed to examinaon by the Internal Revenue Service, and with few excepons, state and local income tax jurisdicons. 45 HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 15 – Leases Lease Obligaons. As of April 3, 2022, we were obligated under operang lease agreements for certain manufacturing facilies, warehouse space, the land on which some of our facilies sit, vehicles and informaon technology equipment. Our leases have remaining lease terms of 1 year to 23 years, some of which include opons to extend the lease for up to 15 years. As of April 3, 2022 and March 28, 2021, our operang lease components with inial or remaining terms in excess of one year were classified on the consolidated balance sheet within right-of-use assets, short-term lease liability and long-term lease liability. Total lease expense was $2.9 million for the twelve months ended April 3, 2022 and $2.8 million for the twelve months ended March 28, 2021, and includes leases less than 12 months in duraon. Other informaon related to our operang leases was as follows: Lease Term and Discount Rate Weighted average remaining lease term (years) Weighted average discount rate Maturies of lease liabilies as of April 3, 2022 were as follows: (In thousands) Fiscal 2023 Fiscal 2024 Fiscal 2025 Fiscal 2026 Fiscal 2027 Thereaer Total Less: Interest Present value of lease liabilies 46 April 3, 2022 March 28, 2021 8.91 2.6 % 9.73 2.7 % Operang Leases 1,889 1,515 1,450 1,388 1,359 5,171 12,772 (1,972) 10,800 $ $ $ HAWKINS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Connued) Note 16 — Segment Informaon We have three reportable segments: Industrial, Water Treatment and Health and Nutrion. The accounng policies of the segments are the same as those described in the summary of significant accounng policies. Product costs and expenses for each segment are based on actual costs incurred along with cost allocaons of shared and centralized funcons. We evaluate performance based on operang income. Reportable segments are defined primarily by product and type of customer. Segments are responsible for the sales, markeng and development of their products and services. Other than our Health and Nutrion segment, the segments do not have separate customer service or purchasing funcons. There are no intersegment sales and no operang segments have been aggregated. Reportable Segments (In thousands) Fiscal Year Ended April 3, 2022: Sales Gross profit Selling, general, and administrave expenses Operang income Idenfiable assets* Capital expenditures Fiscal Year Ended March 28, 2021: Sales Gross profit Selling, general, and administrave expenses Operang income Idenfiable assets* Capital expenditures Fiscal Year Ended March 29, 2020: Sales Gross profit Selling, general, and administrave expenses Operang income Idenfiable assets* Capital expenditures Industrial Water Treatment Health and Nutrion Total $ $ $ $ $ $ $ $ $ 386,938 $ 59,606 28,127 31,479 236,934 $ 18,812 $ 273,361 $ 43,337 27,033 16,304 181,478 $ 13,713 $ 275,224 $ 38,936 24,123 14,813 173,068 $ 14,933 $ 228,133 $ 54,571 31,357 23,214 143,889 $ 8,939 $ 170,004 $ 46,793 24,453 22,340 109,761 $ 6,732 $ 159,895 $ 41,902 19,801 22,101 63,506 $ 9,160 $ 159,470 $ 32,343 15,842 16,501 167,034 $ 761 $ 153,506 $ 33,632 16,398 17,234 166,558 $ 349 $ 105,079 $ 20,079 15,322 4,757 139,780 $ 456 $ 774,541 146,520 75,326 71,194 547,857 28,512 596,871 123,762 67,884 55,878 457,797 20,794 540,198 100,917 59,246 41,671 376,354 24,549 * Unallocated assets not included, consisng primarily of cash and cash equivalents, investments and prepaid expenses, were $19.5 million at April 3, 2022, $14.8 million at March 28, 2021 and $13.0 million at March 29, 2020. 47 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None. ITEM 9A. CONTROLS AND PROCEDURES Evaluaon of Disclosure Controls and Procedures As of the end of the period covered by this Annual Report on Form 10-K, we conducted an evaluaon, under supervision and with the parcipaon of management, including the chief execuve officer and chief financial officer, of the effecveness of the design and operaon of our disclosure controls and procedures pursuant to Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Based upon that evaluaon, our chief execuve officer and chief financial officer concluded that our disclosure controls and procedures are effecve. Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act as controls and other procedures that are designed to ensure that informaon required to be disclosed by us in reports filed with the SEC under the Exchange Act is recorded, processed, summarized and reported within the me periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitaon, controls and procedures designed to ensure that informaon required to be disclosed by us in reports filed under the Exchange Act is accumulated and communicated to our management, including our principal execuve and principal financial officers, or person performing similar funcons, as appropriate to allow mely decisions regarding required disclosure. Management’s Report on Internal Control Over Financial Reporng Our management is responsible for establishing and maintaining adequate internal control over financial reporng as defined in Rules 13a-15(f) and 15d-15(f) of the Securies Exchange Act. Our internal control over financial reporng is designed to provide reasonable assurance regarding the reliability of financial reporng and the preparaon of financial statements for external purposes in accordance with generally accepted accounng principles. Our internal control over financial reporng includes those policies and procedures that (1) pertain to maintenance of records that, in reasonable detail, accurately and fairly reflect the transacons and disposions of our assets; (2) provide reasonable assurance that transacons are recorded as necessary to permit preparaon of the financial statements in accordance with generally accepted accounng principles, and that our receipts and expenditures are being made only in accordance with authorizaons of our management and directors; and (3) provide reasonable assurance regarding prevenon or mely detecon of unauthorized acquision, use or disposion of our assets that could have a material effect on the financial statements. Because of its inherent limitaons, internal control over financial reporng may not prevent or detect misstatements. Projecons of any evaluaon of the effecveness of internal control over financial reporng to future periods are subject to the risk that the controls may become inadequate because of changes in condions, or that the degree of compliance with the policies or procedures may deteriorate. Management assessed the effecveness of our internal control over financial reporng as of April 3, 2022, based on the criteria described in Internal Control - Integrated Framework (2013) issued by the Commiee of Sponsoring Organizaons of the Treadway Commission. In making this assessment as of April 3, 2022, we have excluded the Texas water treatment operaons acquired from NAPCO Chemical Company, Inc. on December 30, 2021. The financial statements of this business comprise less than 4% of total assets and less than 1% of total revenues in our consolidated financial amounts as of and for the year ended April 3, 2022. We have excluded this business because we have not had sufficient me to make an assessment of its internal controls using the COSO criteria in accordance with Secon 404 of the Sarbanes-Oxley Act of 2002. In excluding this business from our assessment, we have considered the “Frequently Asked Quesons” as set forth by the office of the Chief Accountant and the Division of Corporate Finance on June 24, 2004, as revised on September 24, 2007, which acknowledges that it may not be possible to conduct an assessment of an acquired business’s internal control over financial reporng in the period between the consummaon date and the date of management’s assessment and contemplates that such business would be excluded from management’s assessment in the year of acquision. Based on this assessment, management believes that our internal control over financial reporng was effecve as of April 3, 2022. Our independent registered public accounng firm has issued an aestaon report on our internal control over financial reporng for April 3, 2022 which is included in the Report of Independent Registered Public Accounng Firm in Item 8 of this Annual Report on 10-K. Changes in Internal Control Procedures There was no change in our internal control over financial reporng during the fourth quarter of fiscal 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporng. 48 ITEM 9B. OTHER INFORMATION None. ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS Not Applicable. 49 Certain informaon required by Part III is incorporated by reference from Hawkins’ definive Proxy Statement for the Annual Meeng of Shareholders to be held on August 3, 2022 (the “2022 Proxy Statement”). Except for those porons specifically incorporated in this Form 10-K by reference to the 2022 Proxy Statement, no other porons of the 2022 Proxy Statement are deemed to be filed as part of this Form 10-K. PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE Informaon about our Execuve Officers Our current execuve officers, their ages and offices held, are set forth below: Name Patrick H. Hawkins Jeffrey P. Oldenkamp Richard G. Erstad Drew M. Grahek Douglas A. Lange David J. Mangine Theresa R. Moran Shirley A. Rozeboom Office Chief Execuve Officer and President Execuve Vice President, Chief Financial Officer and Treasurer Vice President, General Counsel and Secretary Vice President — Operaons Vice President — Water Treatment Group Vice President — Industrial Group Vice President — Purchasing, Logiscs and Sales Support Vice President — Health and Nutrion Age 51 49 58 52 52 64 59 60 Patrick H. Hawkins has been our Chief Execuve Officer and President and member of our board since 2011. Mr. Hawkins has held the posion of President since 2010. He joined the Company in 1992 and served as the Business Director - Food and Pharmaceucals, a posion he held from 2009 to 2010. Previously he served as Business Manager - Food and Co-Extrusion Products from 2007 to 2009 and Sales Representave - Food Ingredients from 2002 to 2007. He previously served the Company in various other capacies, including Plant Manager, Quality Director and Technical Director. Jeffrey P. Oldenkamp has been our Execuve Vice President, Chief Financial Officer and Treasurer since October 2021. Mr. Oldenkamp joined Hawkins in May 2017 and assumed the role of Chief Financial Officer, Vice President and Treasurer in June 2017. Prior to joining Hawkins, Mr. Oldenkamp was with MTS Systems Corporaon, a supplier of high-performance test systems and sensors, where he served as Chief Financial Officer from 2015 to May 2017 and as Vice President of Finance for the MTS Test business from 2014 to 2015, and with Nilfisk-Advance, Inc., a global manufacturer of professional cleaning equipment, where he served as Americas Operaons Chief Financial Officer and Vice President from 2012 to 2014. Richard G. Erstad has been our Vice President, General Counsel and Secretary since 2008. Mr. Erstad was General Counsel and Secretary of BUCA, Inc., a restaurant company, from 2005 to 2008. Mr. Erstad had previously been an aorney with the corporate group of Faegre & Benson LLP, a law firm, from 1996 to 2005, where his pracce focused on securies law and mergers and acquisions. He is a member of the Minnesota Bar. Drew M. Grahek has been our Vice President - Operaons since September 2018. Prior to joining Hawkins, Mr. Grahek was Adjunct Faculty at the University of Minnesota College of Connuing Educaon and a Business Administrator in the Archdiocese of St. Paul and Minneapolis from June 2017 to June 2018; Director of Service Operaons and Supply Chain with Ulta Beauty, Inc. from April 2016 to June 2017; and Director of Stores with Field and Stream Outdoor Stores, a division of Dick’s Sporng Goods, Inc. from July 2015 to April 2016. Previously, he spent a total of 23 years at Target Corporaon in a variety of operaons, merchandising and property management posions. Douglas A. Lange has been our Vice President - Water Treatment Group since June 2020. Prior to aaining this posion, Mr. Lange served the Company as General Manager and Product Development Manager for the Water Treatment Group aer joining the company in January 2019. Prior to joining the Company, Mr. Lange was with H.B. Fuller Company, a global supplier of special adhesives, where he served as Global Markeng Manager and Product Manager for specialty markets in electronics and wood products from 2011 to January 2019. Mr. Lange served in various roles in the specialty adhesives market for a total of 21 years prior to joining the Company. 50 David J. Mangine has been our Vice President - Industrial Group since 2021. Mr. Mangine served as the Industrial Sales Manager from 2011 to 2021, aer joining Hawkins in 2000 as an Account Manager. Theresa R. Moran has been our Vice President - Purchasing, Logiscs and Sales Support since June 2017. Since joining the Company in 1981, Ms. Moran has served the Company in a variety of posions, including Administraon Operaons Manager from 1999 to 2007, Director - Process Improvement from 2007 unl 2010 and Vice President - Quality and Support from 2010 to June 2017. Shirley A. Rozeboom was named Vice President - Health and Nutrion in April 2019. Ms. Rozeboom had held the posion of Senior Vice President of Sales for Stauber since 2012. Previously, she held the posions of Director of Sales at Stauber from 2008 to 2012 and Account Execuve from 2000 to 2008. The disclosure under the headings “Elecon of Directors,” “Corporate Governance,” and, if applicable, “Delinquent Secon 16(a) Reports” of the 2022 Proxy Statement is incorporated herein by reference. We have adopted a Code of Business Conduct and Ethics that applies to all of our directors and employees, including our principal execuve officer, principal financial officer, controller and other persons performing similar funcons. We have posted the Code of Business Conduct and Ethics on our website located at www.hawkinsinc.com. Hawkins’ Code of Business Conduct and Ethics is also available in print to any shareholder who requests it in wring from our Corporate Secretary. We intend to post on our website any amendment to, or waiver from, a provision of our Code of Business Conduct and Ethics that applies to our principal execuve officer, principal financial officer, controller and other persons performing similar funcons within four business days following the date of such amendment or waiver. We are not including the informaon contained on our website as part of, or incorporang it by reference into, this report. ITEM 11. EXECUTIVE COMPENSATION The disclosure under the heading “Compensaon of Execuve Officers and Directors” in the 2022 Proxy Statement is incorporated herein by reference. ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS The disclosure under the headings “Security Ownership of Management and Beneficial Ownership” and “Equity Compensaon Plan Informaon” in the 2022 Proxy Statement is incorporated herein by reference. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE The disclosure under the headings “Elecon of Directors” and “Related Party Transacons” of the 2022 Proxy Statement is incorporated herein by reference. ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES The disclosure under the heading “Independent Registered Public Accounng Firm’s Fees” of the 2022 Proxy Statement is incorporated herein by reference. 51 ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES (a)(1) FINANCIAL STATEMENTS OF THE COMPANY PART IV The following financial statements of Hawkins, Inc. are filed as part of this Annual Report on Form 10-K: Reports of Independent Registered Public Accounng Firms. Consolidated Balance Sheets at April 3, 2022 and March 28, 2021. Consolidated Statements of Income for the fiscal years ended April 3, 2022, March 28, 2021 and March 29, 2020. Consolidated Statements of Comprehensive Income for the fiscal years ended April 3, 2022, March 28, 2021 and March 29, 2020. Consolidated Statements of Shareholders’ Equity for the fiscal years ended April 3, 2022, March 28, 2021, and March 29, 2020. Consolidated Statements of Cash Flows for the fiscal years ended April 3, 2022, March 28, 2021, and March 29, 2020. Notes to Consolidated Financial Statements. (a)(2) FINANCIAL STATEMENT SCHEDULES OF THE COMPANY The addional financial data listed below is included as a schedule to this Annual Report on Form 10-K and should be read in conjuncon with the financial statements presented in Part II, Item 8. Schedules not included with this addional financial data have been omied because they are not required, or the required informaon is included in the financial statements or the notes. The following financial statement schedule for the fiscal years 2022, 2021 and 2020. Schedule II — Valuaon and Qualifying Accounts. (a)(3) EXHIBITS 52 Exhibit Index Exhibit Descripon 3.1 Restated Arcles of Incorporaon. (1) 3.2 Amended and Restated By-Laws. (2) 4.1 Descripon of Securies. (3) 10.1* Hawkins, Inc. 2010 Omnibus Incenve Plan. (4) 10.2* Hawkins, Inc. Execuve Severance Plan. (5) 10.3* Employee Stock Purchase Plan, as amended. (6) 10.4 Second Amended and Restated Credit Agreement, dated as of March 31, 2022, among the Company, U.S. Bank Naonal Associaon, and certain financial instuons. (7) 10.5* Hawkins, Inc. 2019 Equity Incenve Plan. (8) 10.6* Form of Performance Stock Unit Award Noce and Restricted Stock Agreement under the Company’s 2019 Equity Incenve Plan. (9) 10.7* Nine Year LTI with Shirley Rozeboom. (10) 16.1 Correspondence from KPMG LLP dated February 11, 2020. (11) 21 Subsidiaries of the registrant. 23.1 Consent of Grant Thornton LLP. 23.2 24.1 31.1 Consent of KPMG LLP. Powers of Aorney. Cerficaon by Chief Cerficaon by Chief Execuve Officer pursuant to Rule 13a-14(a) of the Exchange Act. Officer pursuant to Rule 13a-14(a) of the Exchange Act. Method of Filing Incorporated by Reference Incorporated by Reference Incorporated by Reference Incorporated by Reference Incorporated by Reference Incorporated by Reference Incorporated by Reference Incorporated by Reference Incorporated by Reference Incorporated by Reference Incorporated by Reference Filed Electronically Filed Electronically Filed Electronically Filed Electronically Filed Electronically 31.2 Cerficaon by Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act. Filed Electronically 32.1 Secon 1350 Cerficaon by Chief Execuve Officer. 32.2 Secon 1350 Cerficaon by Chief Financial Officer. 101 Financial statements from the Annual Report on Form 10-K of Hawkins, Inc. for the period ended April 3, 2022, filed with the SEC on May 18, 2022, formaed in Inline Extensible Business Reporng Language (iXBRL): (i) the Consolidated Balance Sheets at April 3, 2022 and March 28, 2021 (ii) the Consolidated Statements of Income for the fiscal years ended April 3, 2022, March 28, 2021, and March 29, 2020, (iii) the Consolidated Statements of Comprehensive Income for the fiscal years ended April 3, 2022, March 28, 2021, and March 29, 2020, (iv) the Consolidated Statements of Shareholders’ Equity for the fiscal years ended April 3, 2022, March 28, 2021, and March 29, 2020, (v) Consolidated Statements of Cash Flows for the fiscal years ended April 3, 2022, March 28, 2021, and March 29, 2020, and (iv) Notes to Consolidated Financial Statements. Filed Electronically Filed Electronically Filed Electronically 104 Cover Page Interacve Data File (embedded within the inline XBRL document) Filed Electronically * Management contract or compensaon plan or arrangement required to be filed as an exhibit to this Annual Report on Form 10-K. (1) Incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K dated February 26, 2021 and filed March 2, 2021. (2) Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K dated October 28, 2009 and filed November 3, 2009. (3) Incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed June 2,2021. (4) Incorporated by reference to Exhibit 10.1 to the Company’s Registraon Statement on Form S-8 filed June 6, 2011. (5) Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended July 3, 2011. (6) Incorporated by reference to Exhibit 99.1 to the Company’s Registraon Statement on Form S-8 filed November 2, 2018. (7) Incorporated by reference to Exhibit 10.1 to the Company’s Registraon Statement on Form 8-K filed December 3, 2018. (8) Incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2019. (9) Incorporated by reference to Exhibit 10.10 to the Company’s Annual Report on Form 10-K filed May 20,2020. (10) Incorporated by reference to Exhibit 10.7 to the Company’s Annual Report on Form 10-K filed June 2,2021. (11) Incorporated by reference to Exhibit 16.1 to the Company’s Current Report on Form 8-K dated February 11, 2020. ITEM 16. FORM 10-K SUMMARY None Pursuant to the requirements of Secon 13 or 15(d) of the Securies Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SIGNATURES Dated: May 18, 2022 HAWKINS, INC. By /s/ Patrick H. Hawkins Patrick H. Hawkins Chief Execuve Officer and President Pursuant to the requirements of the Securies Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacies and on the dates indicated. Signature Date Title /s/ Patrick H. Hawkins Patrick H. Hawkins /s/ Jeffrey P. Oldenkamp Jeffrey P. Oldenkamp * James A. Faulconbridge * Mary J. Schumacher * Jeffrey E. Spethmann * Daniel J. Stauber * Yi "Faith" Tang * James T. Thompson * Jeffrey L. Wright Chief Execuve Officer, President and Director (principal execuve officer) Execuve Vice President and Chief Financial Officer (principal financial officer and principal accounng officer) Director Director Director Director Director Director Director May 18, 2022 May 18, 2022 May 18, 2022 May 18, 2022 May 18, 2022 May 18, 2022 May 18, 2022 May 18, 2022 May 18, 2022 * Patrick H. Hawkins, by signing his name hereto, does hereby sign this document on behalf of each of the above-named directors of the registrant pursuant to Powers of Aorney duly executed by such persons. By: /s/ Patrick H. Hawkins Patrick H. Hawkins Aorney-in-fact SCHEDULE II HAWKINS, INC. VALUATION AND QUALIFYING ACCOUNTS FOR THE FISCAL YEARS ENDED April 3, 2022, March 28, 2021 AND March 29, 2020 Descripon Reserve deducted from asset to which it applies: Fiscal Year Ended April 3, 2022: Allowance for credit losses Fiscal Year Ended March 28, 2021: Allowance for credit losses Fiscal Year Ended March 29, 2020: Allowance for credit losses $ $ $ Balance at Beginning of Year Charged to Costs and Expenses Addions Charged to Other Accounts (In thousands) Deducons Write-Offs Balance at End of Year 497 $ 784 $ 620 $ — $ — $ 448 $ — $ — $ — $ (130) $ (287) $ (284) $ 367 497 784 Subsidiaries of Hawkins, Inc. Exhibit 21 Subsidiary Stauber Holdings, Inc. Stauber Performance Ingredients, Inc., a subsidiary of Stauber Holdings, Inc. NAPCO Chemical Company, Inc. State of Organizaon Minnesota Minnesota Minnesota Consent of Independent Registered Public Accounng Firm Exhibit 23.1 The Board of Directors Hawkins, Inc.: We have issued our reports dated May 18, 2022, with respect to the consolidated financial statements and internal control over financial reporng included in the Annual Report of Hawkins, Inc. on Form 10-K for the year ended April 3, 2022. We consent to the incorporaon by reference of said reports in the Registraon Statements of Hawkins, Inc. on Forms S-8 (File Nos. 333-87582, 333-123080, 333-172761, 333-174735, 333-228128 and 333-234432). /s/ Grant Thornton LLP Minneapolis, Minnesota May 18, 2022 Consent of Independent Registered Public Accounng Firm Exhibit 23.2 The Board of Directors Hawkins, Inc.: We consent to the incorporaon by reference in the registraon statements (No. 333-87582, 333-123080, 333-172761, 333-174735, 333-228128, 333- 234432) on Form S-8 of our report dated May 20, 2020, except as to the stock split and par value adjustment as described in Note 1, which are as of June 2, 2021, with respect to the consolidated financial statements of Hawkins, Inc. /s/ KPMG LLP Minneapolis, Minnesota May 18, 2022 HAWKINS, INC. Power of Aorney The undersigned director of Hawkins, Inc., a Minnesota corporaon (the “Company”), does hereby make, constute and appoint Patrick H. Hawkins and Jeffrey P. Oldenkamp, and either of them, the undersigned’s true and lawful aorneys-in-fact and agents, with power of substuon and resubstuon, for the undersigned and in the undersigned’s name, place and stead, to sign and affix the undersigned’s name as such director of the Company to an Annual Report on Form 10-K for the fiscal year ended April 3, 2022 or other applicable form, and any amendments thereto, to be filed by the Company with the U.S. Securies and Exchange Commission, Washington, D.C. (the “SEC”), and to file the same with all exhibits thereto and other supporng documents in connecon therewith with the SEC, granng unto said aorneys-in-fact and agents, and each of them, full power and authority to do and to perform any and all acts necessary or incidental to the performance and execuon of the powers herein expressly granted. IN WITNESS WHEREOF, the undersigned has executed this Power of Aorney as of the date set forth below. /s/ James A. Faulconbridge James A. Faulconbridge April 27, 2022 HAWKINS, INC. Power of Aorney The undersigned director of Hawkins, Inc., a Minnesota corporaon (the “Company”), does hereby make, constute and appoint Patrick H. Hawkins and Jeffrey P. Oldenkamp, and either of them, the undersigned’s true and lawful aorneys-in-fact and agents, with power of substuon and resubstuon, for the undersigned and in the undersigned’s name, place and stead, to sign and affix the undersigned’s name as such director of the Company to an Annual Report on Form 10-K for the fiscal year ended April 3, 2022 or other applicable form, and any amendments thereto, to be filed by the Company with the U.S. Securies and Exchange Commission, Washington, D.C. (the “SEC”), and to file the same with all exhibits thereto and other supporng documents in connecon therewith with the SEC, granng unto said aorneys-in-fact and agents, and each of them, full power and authority to do and to perform any and all acts necessary or incidental to the performance and execuon of the powers herein expressly granted. IN WITNESS WHEREOF, the undersigned has executed this Power of Aorney as of the date set forth below. /s/ Mary J. Schumacher Mary J. Schumacher April 27, 2022 HAWKINS, INC. Power of Aorney The undersigned director of Hawkins, Inc., a Minnesota corporaon (the “Company”), does hereby make, constute and appoint Patrick H. Hawkins and Jeffrey P. Oldenkamp, and either of them, the undersigned’s true and lawful aorneys-in-fact and agents, with power of substuon and resubstuon, for the undersigned and in the undersigned’s name, place and stead, to sign and affix the undersigned’s name as such director of the Company to an Annual Report on Form 10-K for the fiscal year ended April 3, 2022 or other applicable form, and any amendments thereto, to be filed by the Company with the U.S. Securies and Exchange Commission, Washington, D.C. (the “SEC”), and to file the same with all exhibits thereto and other supporng documents in connecon therewith with the SEC, granng unto said aorneys-in-fact and agents, and each of them, full power and authority to do and to perform any and all acts necessary or incidental to the performance and execuon of the powers herein expressly granted. IN WITNESS WHEREOF, the undersigned has executed this Power of Aorney as of the date set forth below. /s/ Jeffrey E. Spethmann Jeffrey E. Spethmann April 27, 2022 HAWKINS, INC. Power of Aorney The undersigned director of Hawkins, Inc., a Minnesota corporaon (the “Company”), does hereby make, constute and appoint Patrick H. Hawkins and Jeffrey P. Oldenkamp, and either of them, the undersigned’s true and lawful aorneys-in-fact and agents, with power of substuon and resubstuon, for the undersigned and in the undersigned’s name, place and stead, to sign and affix the undersigned’s name as such director of the Company to an Annual Report on Form 10-K for the fiscal year ended April 3, 2022 or other applicable form, and any amendments thereto, to be filed by the Company with the U.S. Securies and Exchange Commission, Washington, D.C. (the “SEC”), and to file the same with all exhibits thereto and other supporng documents in connecon therewith with the SEC, granng unto said aorneys-in-fact and agents, and each of them, full power and authority to do and to perform any and all acts necessary or incidental to the performance and execuon of the powers herein expressly granted. IN WITNESS WHEREOF, the undersigned has executed this Power of Aorney as of the date set forth below. /s/ Daniel J. Stauber Daniel J. Stauber April 27, 2022 HAWKINS, INC. Power of Aorney The undersigned director of Hawkins, Inc., a Minnesota corporaon (the “Company”), does hereby make, constute and appoint Patrick H. Hawkins and Jeffrey P. Oldenkamp, and either of them, the undersigned’s true and lawful aorneys-in-fact and agents, with power of substuon and resubstuon, for the undersigned and in the undersigned’s name, place and stead, to sign and affix the undersigned’s name as such director of the Company to an Annual Report on Form 10-K for the fiscal year ended April 3, 2022 or other applicable form, and any amendments thereto, to be filed by the Company with the U.S. Securies and Exchange Commission, Washington, D.C. (the “SEC”), and to file the same with all exhibits thereto and other supporng documents in connecon therewith with the SEC, granng unto said aorneys-in-fact and agents, and each of them, full power and authority to do and to perform any and all acts necessary or incidental to the performance and execuon of the powers herein expressly granted. IN WITNESS WHEREOF, the undersigned has executed this Power of Aorney as of the date set forth below. /s/ Yi “Faith” Tang Yi “Faith” Tang April 27, 2022 HAWKINS, INC. Power of Aorney The undersigned director of Hawkins, Inc., a Minnesota corporaon (the “Company”), does hereby make, constute and appoint Patrick H. Hawkins and Jeffrey P. Oldenkamp, and either of them, the undersigned’s true and lawful aorneys-in-fact and agents, with power of substuon and resubstuon, for the undersigned and in the undersigned’s name, place and stead, to sign and affix the undersigned’s name as such director of the Company to an Annual Report on Form 10-K for the fiscal year ended April 3, 2022 or other applicable form, and any amendments thereto, to be filed by the Company with the U.S. Securies and Exchange Commission, Washington, D.C. (the “SEC”), and to file the same with all exhibits thereto and other supporng documents in connecon therewith with the SEC, granng unto said aorneys-in-fact and agents, and each of them, full power and authority to do and to perform any and all acts necessary or incidental to the performance and execuon of the powers herein expressly granted. IN WITNESS WHEREOF, the undersigned has executed this Power of Aorney as of the date set forth below. /s/ James T. Thompson James Thompson April 27, 2022 HAWKINS, INC. Power of Aorney The undersigned director of Hawkins, Inc., a Minnesota corporaon (the “Company”), does hereby make, constute and appoint Patrick H. Hawkins and Jeffrey P. Oldenkamp, and either of them, the undersigned’s true and lawful aorneys-in-fact and agents, with power of substuon and resubstuon, for the undersigned and in the undersigned’s name, place and stead, to sign and affix the undersigned’s name as such director of the Company to an Annual Report on Form 10-K for the fiscal year ended April 3, 2022 or other applicable form, and any amendments thereto, to be filed by the Company with the U.S. Securies and Exchange Commission, Washington, D.C. (the “SEC”), and to file the same with all exhibits thereto and other supporng documents in connecon therewith with the SEC, granng unto said aorneys-in-fact and agents, and each of them, full power and authority to do and to perform any and all acts necessary or incidental to the performance and execuon of the powers herein expressly granted. IN WITNESS WHEREOF, the undersigned has executed this Power of Aorney as of the date set forth below. /s/ Jeffrey L. Wright Jeffrey L. Wright April 27, 2022 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 31.1 CERTIFICATIONS I, Patrick H. Hawkins, cerfy that: 1. I have reviewed this annual report on Form 10-K of Hawkins, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial informaon included in this report, fairly present in all material respects the financial condion, results of operaons and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other cerfying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporng (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material informaon relang to the registrant, including its consolidated subsidiaries, is made known to us by others within those enes, parcularly during the period in which this report is being prepared; b) designed such internal control over financial reporng, or caused such internal control over financial reporng to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporng and the preparaon of financial statements for external purposes in accordance with generally accepted accounng principles; c) evaluated the effecveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effecveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluaon; and d) disclosed in this report any change in the registrant’s internal control over financial reporng that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporng; and 5. The registrant’s other cerfying officer and I have disclosed, based on our most recent evaluaon of internal control over financial reporng, to the registrant’s auditors and the audit commiee of the registrant’s board of directors (or persons performing the equivalent funcons): a) all significant deficiencies and material weaknesses in the design or operaon of internal control over financial reporng which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial informaon; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporng. Date: May 18, 2022 /s/ Patrick H. Hawkins Patrick H. Hawkins Chief Execuve Officer and President CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 31.2 CERTIFICATIONS I, Jeffrey P. Oldenkamp, cerfy that: 1. I have reviewed this annual report on Form 10-K of Hawkins, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial informaon included in this report, fairly present in all material respects the financial condion, results of operaons and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other cerfying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporng (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material informaon relang to the registrant, including its consolidated subsidiaries, is made known to us by others within those enes, parcularly during the period in which this report is being prepared; b) designed such internal control over financial reporng, or caused such internal control over financial reporng to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporng and the preparaon of financial statements for external purposes in accordance with generally accepted accounng principles; c) evaluated the effecveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effecveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluaon; and d) disclosed in this report any change in the registrant’s internal control over financial reporng that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporng; and 5. The registrant’s other cerfying officer and I have disclosed, based on our most recent evaluaon of internal control over financial reporng, to the registrant’s auditors and the audit commiee of the registrant’s board of directors (or persons performing the equivalent funcons): a) all significant deficiencies and material weaknesses in the design or operaon of internal control over financial reporng which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial informaon; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporng. Date: May 18, 2022 /s/ Jeffrey P. Oldenkamp Jeffrey P. Oldenkamp Execuve Vice President and Chief Financial Officer CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 32.1 In connecon with the Annual Report of Hawkins, Inc. (the Company) on Form 10-K for the period ended April 3, 2022, as filed with the Securies and Exchange Commission on the date hereof (the Report), I, Patrick H. Hawkins, Chief Execuve Officer and President of the Company, cerfy, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of secon 13(a) or 15(d) of the Securies Exchange Act of 1934; and (2) The informaon contained in the Report fairly presents, in all material respects, the financial condion and results of operaons of the Company. /s/ Patrick H. Hawkins Patrick H. Hawkins Chief Execuve Officer and President May 18, 2022 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit 32.2 In connecon with the Annual Report of Hawkins, Inc. (the Company) on Form 10-K for the period ended April 3, 2022, as filed with the Securies and Exchange Commission on the date hereof (the Report), I, Jeffrey P. Oldenkamp, Chief Financial Officer of the Company, cerfy, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that: (1) The Report fully complies with the requirements of secon 13(a) or 15(d) of the Securies Exchange Act of 1934; and (2) The informaon contained in the Report fairly presents, in all material respects, the financial condion and results of operaons of the Company. /s/ Jeffrey P. Oldenkamp Jeffrey P. Oldenkamp Execuve Vice President and Chief Financial Officer May 18, 2022

Continue reading text version or see original annual report in PDF format above